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ABSTRACT
Currently, prostate cancer is the second most frequently diagnosed cancer in European Western
countries, specially in Nothern Europe. Compared to other parts of the world, Europe is among
the regions with highest incidence. In particular, prostate cancer is a relevant health problem
in Spain, where the mean incidence was 57.2/100 000 men-year in 2008 (Ferlay et al., 2010)
Increasing age and some genetic and ethnic risk factors have been identified as causes of prostate
cancer development. In this regard, the prostate specific antigen (PSA) has become the main
marker used for the early detection of prostate cancer, although the precise contribution of
this variable to predict disease incidence is not yet very known. Consequently, there is a sense
important clinical need for achieving a better knowledge of the marker, so that the increasing
number of diagnosed men can be appropriately managed in order to avoid overdiagnosis, i.e.,
cases in which prostate cancer would have never been detected in the subject’s lifetime without
screening and would have never progressed to lethal disease. To solve this uncertainty, the
European Randomized Screening for Prostate Cancer study, ERSPC, was initiated in the early
90’s of the last century in order to evaluate the effect of the PSA testing on events rates from
prostate cancer.
This work analyzes with the data of the Spanish branch of the ERSPC study, where among
other longitudinal covariates, PSA repeated measurements were taken on the recruited men
over time. Moreover, prostate cancer incidence was recorded for each of these subjects. Thus,
the aim of this work is to assess the association between the subject-specific profile evolution
with the prostate cancer risk, performing a joint analysis of longitudinal and time-to-event data.
In the joint modeling approach, the longitudinal covariates are assumed to be of parametric form
with random effects (Laird and Ware, 1982), such as a linear mixed effects model, while the Cox
proportional hazards model (Cox, 1972) is used to describe the survival information.
The proposed joint modeling techniques were applied to the motivating PCa Dataset. The
joint model’s fixed parameters were estimated with the maximum likelihood method using the
Expectation-Maximization algorithm, and for the random effects an empirical Bayes approach
was employed. Therefore, a joint model was obtaining connecting the longitudinal and survival
processes. The main goal was to measure the association between the true longitudinal PSA
response (i.e., without measurement error) and the risk for prostate cancer diagnosis, while
accounting the special features of each subject. The joint model’s assumptions were validated
by residual plots, and in the last part of the study the joint modeling results were summarized
and discussed, as well as considerations on further areas of research.
All the analysis included in this work have been implemented in the R software environment for
statistical computing and graphics, using (among others) the following available packages: nlme
(Pinheiro et al.), survival (Therneau, 2012) and JM (Rizopoulos, 2010).

RESUM
En l’actualitat, el ca`ncer de pro`stata e´s el segon tipus de ca`ncer me´s diagnosticat als pa¨ısos
d’Europa occidental, amb un gran nombre d’afectats en aquells pa¨ısos europeus me´s septentri-
onals. En comparacio´ amb altres parts del mo´n, Europa es troba entre les regions amb un major
nivell de repercussio´ de la malaltia. Particularment, el ca`ncer de pro`stata constitueix un greu
problema de salut pu´blica a Espanya, on la incide`ncia mitjana va ser de 57.2/100 000 homes-any
durant 2008 (Ferlay et al., 2010).
L’augment de l’edat i alguns factors de risc de tipus gene`tic i e`tnic han estat tradicionalment
identificats com a causes que afavoreixen el desenvolupament de ca`ncer de pro`stata. En aquest
punt, el denominat ant´ıgen espec´ıfic prosta`tic (PSA) s’ha convertit en el principal biomarcador
utilitzat per a la deteccio´ precoc¸ de la malaltia, encara que l’exacta incide`ncia d’aquesta vari-
able es´ avui en dia molt desconeguda. Existeix per tant una necessitat cl´ınica d’assolir un millor
coneixement d’aquest biomarcador, de manera que el cada cop me´s elevat nombre d’homes di-
agnosticats pugui ser adequ¨adament tractat i s’evitin casos de sobrediagno`stic, e´s a dir, aquells
casos en que` el ca`ncer de pro`stata mai hauria estat detectat fora d’un proce´s de cribatge ni tam-
poc hauria tingut una progressio´ letal per a la salut del subjecte. Per a millorar el coneixement
sobre aquesta incertesa, es va iniciar a principis dels anys 90 del segle passat l’estudi European
Randomized Screening for Prostate Cancer, ERSPC, evaluant l’efecte de la prova de nivell de
PSA en la deteccio´ de nous casos de ca`ncer de pro`stata.
El present treball analitza les dades corresponents a la seccio´ espanyola de l’estudi ERSPC, on
entre d’altres variables es van obtenir en els subjectes de l’estudi mesures repetides del valor
de la PSA al llarg del temps. D’altra banda, tambe´ es va recollir la incide`ncia del ca`ncer de
pro`stata entre cadascun dels subjectes de l’estudi. D’aquesta forma, l’objectiu d’aquest treball
ha estat el poder avaluar si hi ha relaci entre l’evolucio´ particular d’un determinat subjecte amb
el risc d’experimentar la malaltia, realitzant per a aixo` una modelitzacio´ conjunta de les dades
longitudinals i de supervive`ncia. Sota una aproximacio´ de tipus joint modeling, les covariants
longitudinals son tractades de forma parame`trica amb la incorporacio´ d’efectes aleatoris (Laird
and Ware, 1982), mentre que les dades de supervive`ncia acostumen a la literatura a ser tractades
amb el model de riscos proporcionals desenvolupat per Cox (Cox, 1972).
Les te`cniques de joint modeling van ser aplicades al conjunt de dades de l’estudi, PCa Dataset.
Els para`metres del model es van estimar mitjanc¸ant el me`tode de ma`xima versemblanc¸a amb
l’algoritme Expectation-Maximization, i per a predir els efectes aletoris es va utilitzar una aprox-
imacio´ del tipus Empirical Bayes. Aix´ı, es va poder obtenir un model conjunt que connecte´s
els processos longitudinal i de supervive`ncia. S’ha pogut doncs mesurar el grau d’asscociacio´
entre la resposta longitudinal real (e´s a dir, sense estar sotmesa a error de mesura) i el risc
de diagno`stic de ca`ncer de pro`stata, tot considerant les particularitats de cada individu. Les
hipo`tesis han estat validades per gra`fics de residus, i es resumeixen els resultats de la mod-
elitzacio´ conjunta, aix´ı com tambe´ es presenten una se`rie de consideracions sobre futures a`rees
de recerca en el tema.
Totes les ana´lisis incloses en aquest treball han estat implementats amb el programa estad´ıstic
de lliure acce´s R, utilitzat per a la modelitzacio´ de dades i la realitzacio´ de gra`fics. Entre d’altres
paquets del programa, s’han fet servir els segu¨ents: nlme (Pinheiro et al.), survival (Therneau,
2012) i JM (Rizopoulos, 2010).

RESUMEN
En la actualidad, el ca´ncer de pro´stata es el segundo tipo de ca´ncer ma´s diagnosticado en los
pa´ıses de Europa occidental, con un gran nu´mero de afectados en aquellos pa´ıses ma´s septen-
trionales. En comparacio´n con otras partes del mundo, Europa se halla entre las regiones con
una mayor nivel de repercusio´n de la enfermedad. En concreto, el ca´ncer de pro´stata constituye
una grave problema de salud pu´blica en Espan˜a, donde la incidencia media fue de 57.2/100 000
hombres-an˜o durante 2008 (Ferlay et al., 2010).
El aumento de la edad y algunos factores de riesgo de tipo tanto gene´tico como e´tnico han sido
tradicionalmente identificados como causas que favorecen el desarrollo del ca´ncer de pro´stata. En
este punto, el denominado ant´ıgeno espec´ıfico prosta´tico (PSA) se ha convertido en el principal
biomarcador utilizado para la deteccio´n precoz de la enfermedad, si bien que la exacta incidencia
de esta variable es a d´ıa de hoy muy desconocida. Existe por tanto una necesidad cl´ınica
imperiosa de tener un mejor conocimiento de este marcador biolo´gico, de manera que el cada
vez mayor nu´mero de hombres diagnosticados pueda ser adecuadamente tratado y se eviten casos
de sobrediagno´stico, es decir, casos en los que el ca´ncer de pro´stata nunca se habr´ıa detectado
fuera de un proceso de cribado, ni tampoco habr´ıa tenido una progresio´n de consecuencias
letales para la salud del sujeto. Para solventar esta incertidumbre, a principios de los an˜os
90 del siglo pasado se puso en marcha el estudio European Randomized Screening for Prostate
Cancer, ERSPC, evaluando el efecto de la prueba de nivel de PSA en la deteccio´n de nuevos
casos de ca´ncer de pro´stata.
El trabajo analiza los datos de la seccio´n espan˜ola del estudio ERSPC, donde, entre otras
variables, se recogio´ en los diferentes sujetos una serie de medidas repetidas del valor de la PSA
a lo largo del tiempo. Tambie´n se registro´ la incidencia del ca´ncer de pro´stata en cada uno
los sujetos. As´ı, el objetivo del trabajo es relacionar la evolucio´n particular de un determinado
individuo con su riesgo de experimentar la enfermedad, modelizando de forma conjunta los
datos longitudinales y de supervivencia. Bajo una aproximacio´n de tipo joint modeling, las
covariantes longitudinales son tratadas de forma parame´trica con la incorporacio´n de efectos
aleatorios (Laird and Ware, 1982), mientras que los datos de supervivencia acostumbran a ser
tratados con el modelo de riesgos proporcionales desarrollado por Cox (Cox, 1972).
Les te´cnicas de joint modeling se aplicaron sobre el conjunto de sujetos del estudio, PCa Dataset.
Los para´metros del modelo se estimaron mediante el me´todo de ma´xima verosimilitud con
el algoritmo Expectation-Maximization, y para predecir los efectos aleatorios se empleo´ una
aproximacio´n del tipo Empirical Bayes. As´ı, se ha obtenido un modelo que conecta los procesos
longitudinal y de supervivencia, permitiendo medir el grado de asociacio´n entre la respuesta
longitudinal real (es decir, sin error de medida) y el riesgo de diagno´stico de ca´ncer de pro´stata,
considerando las particularidades de cada individuo. Las hipo´tesis fueron validadas por gra´ficos
de residuos, y se resumen los resultados de la modelizacio´n conjunta, as´ı como tambie´n se
presentan una serie de consideraciones sobre futuras l´ıneas de investigacio´n en el tema.
Todos los ana´lisis incluidos en este trabajo han sido implementados con el programa estad´ıstico
de libre acceso R, utilitzado para la modelizacio´n de datos y la realizacio´n de gra´ficos. Entre
otros paquetes del programa, se han utilizado los sigu¨ientes: nlme (Pinheiro et al.), survival
(Therneau, 2012) y JM (Rizopoulos, 2010).
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CHAPTER 1
INTRODUCTION AND GOALS
1.1 Motivation
It has become increasingly common in survival studies to record the values of key longitudinal
covariates until the occurrence of some particular event of interest E on a subject. For example,
in many medical studies, it is usually collected patients’ information repeatedly over time, being
of interest the time to recovery or recurrence of a disease. Some longitudinal covariates (e.g.,
biomarkers) may involve measurement error due to biological processes inherent to the subject or
may be affected by non-random dropout. All these difficulties can be circumvented by including
random effects in the longitudinal covariates, for example through a linear mixed-effects model,
and modeling the longitudinal and time-to-event data jointly rather than separately. Thus, the
so-called Joint Models consider these two data types together into a single statistical model, so
that one can assess the association between the longitudinal measurements and the time to the
event of interest under study.
If the analysis focuses on longitudinal data, informative missing values need to be addressed since
dropouts are very common in longitudinal studies, whereas if the analysis focuses on survival data,
time-dependent covariates must be incorporated as the times to event may be associated with
the covariate trajectories. Sometimes, the main interest may lie in the association between the
longitudinal process and survival process.
In general, a joint modeling approach is required in mainly three situations:
1. The interest is on the event outcome and one wishes to account for the effect of the longitudinal
outcome as a time-dependent covariate. Taditional approaches for analyzing time-to-event data
(such as the partial likelihood for the Cox proportional hazards models) are not applicable if
the time-dependent covariates are internal or endogenous.
2. The interest is on the longitudinal outcome. In this case the occurrence of events causes dropout
since no longitudinal measurements are available at and after the event time. When this dropout
is non at random (i.e., the probability of dropout depends on unobserved longitudinal responses),
then bias may arise from an analysis that ignores the dropout process.
3. The main interest lies in the association between the true longitudinal profile of the subject
and the survival time. To solve this question and obtain valid inferences, the longitudinal and
dropout process must be jointly modeled.
1.2 Scope and aims of the work
This study is motivated by the European Randomized Screening for Prostate Cancer study, ERSPC,
which is the world’s largest randomized prostate cancer screening study, where the objective was to
investigate whether early detection and treatment of prostate cancer might reduce disease-specific
mortality and also help to identify men at risk. In particular, the motivating dataset corresponds
to the screening arm of the ERSPC Spanish branch. The main aim of this research work is to show
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how joint models can be used to incorporate past and current true PSA levels into a predictive
model of prostate cancer with the objective of refining the estimation of the time until prostate
cancer diagnosis event. To achieve this, the specific goals are the following:
1. To analyze the dataset derived from the Spanish section of ERSPC study, considering the pro-
vided information from a dual approach: longitudinal PSA data analysis and survival time until
the occurrence of the prostate cancer occurrence.
2. To understand all the mathematic methodology related to the longitudinal and survival models,
laying the principles of a jointly modelization for both type of models through the so-called joint
models. In particular, the present study takes as a main reference the progress made in this field
by professor Rizopoulos.
3. To apply the joint modeling techniques to a particular case study, such as the referred to the
Spanish section from ERSPC project. As a main result, the joint model implementation allows
to link a particular subject-specific trend over time to the probability of event diagnosis.
4. To assess the joint goodness-of-fit of the estimated joint model and illustrate how time to prostate
cancer diagnosis can be predicted for each individual. This goal enables professionals to make
a personalized diagnosis of how disease will evolve, that means, make predictions taking into
account the specific characteristics of each individual.
The rest of the paper is organized as follows. Chapter 2 presents a description of the motivating
dataset, the Spanish ERSPC data. In Chapter 3, the joint model methodology for longitudinal
measurements and time-to-event data is introduced. Chapter 4 shows the results of joint modeling
approach for longitudinal PSA responses and survival time until prostate cancer diagnosis, includ-
ing the joint model diagnostics and dynamic survival predictions. Finally, Chapter 5 contains a
discussion focused on the impact of longitudinal PSA values and baseline covariates on prostate
cancer risk, and also the potential areas of future research.
CHAPTER 2
PROSTATE CANCER AND THE ERSPC PROJECT
2.1 Problematic associated to prostate cancer
2.1.1 Prostate cancer incidence and risk factors
Prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive
system. Most prostate cancers are slow growing and they do not dramatically worsen over time,
so an “active surveillance” with biopsy tests may be a good option for these cases. However, there
are cases of aggressive prostate cancers which need a more intensive treatment that includes tumor
removal through surgery or radiation therapy. The cancer cells may metastasize (spread) from the
prostate to other parts of the body, particularly the bones and lymph nodes. Prostate cancer may
cause pain, difficulty in urinating or problems during sexual intercourse. Other symptoms can be
potentially developed during later stages of the disease.
Rates of detection of prostate cancer vary widely across the world (Figure 2.1), with South and East
Asia detecting less frequently than in Europe, and especially in the United States (Swerdlow et al.,
2008). Prostate cancer tends to develop in men over the age of fifty, and it is the sixth leading cause
of cancer death among men worldwide with an estimated 899 100 new cases and 258 100 deaths in
2008. In particular, 370 700 new cases were detected in Europe, and 89 600 men died of the disease
(Ferlay et al., 2010). However, many men with prostate cancer never have symptoms, undergo no
therapy, and eventually die of other unrelated causes. Many factors, including genetics and diet,
have been implicated in the development of prostate cancer.
Figure 2.1. Age-standardized prostate cancer mortality rates / 100 000 globally in 2008 (Swerdlow
et al., 2008).
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In terms of disease research, most studies (Brandt et al., 2003; Schro¨der et al., 2012) predict the
presence of prostate cancer together based on three types of test: the recorded level of prostate-
specific antigen (tPSA or simply PSA), the value of prostate-specific antigen ratio (PSARAT ) and
by physical examination of the subject. Below, we describe briefly the main diagnostic tests that
can lead to the diagnosis of the disease:
1. Total prostate specific antigen, PSA
The prostate-specific antigen is a protein found in the blood, which is produced almost exclusively
by epithelial prostatic cells, and it is usually measured in nanograms per milliliter of blood
(ng/ml). It represents a useful biomarker which is used for the early detection of prostate
cancer. In this regard, a high blood PSA level tends to be associated with an increased risk of
having prostate cancer. However, an elevated PSA level may also be due to other causes: a) an
increase in normal prostate glands like in benign prostate hyperplasia (BPH) or b) an increased
leakage of PSA into the bloodstream due to infectious processes or obstruction. Consequently,
an elevated PSA score often does not necessarily indicate the presence of disease. Moreover, a
low PSA level does not exclude the possibility of prostate cancer: even in very low PSA ranges,
a considerable prostate cancer detection rate has been described.
2. Prostate specific antigen ratio, PSARAT
It is defined as the relationship between free PSA (FPSA, ng/ml) and total PSA (ng/ml):
PSARAT = FPSA/PSA. The free PSA is the small PSA amount in the blood which is not
protein bound. The importance of PSA ratio is that the risk of cancer diagnosis increases
significantly if the free to total ratio is less than a certain percentage (typically 15%−25%).
3. Physical examination of the subject
• Digital Rectal examination, DRE : A digital examination is a simple technique where the
doctor inserts a lubricated finger through the subjects rectum to feel for suspicious areas of
the prostate gland. This allows to check those lumpy or abnormal areas on the prostate. The
exam is only limited to detecting lesions protruding the surface of the prostate. A digital
rectal exam is done for men as part of a complete physical examination to check the prostate
gland size.
• Transrectal ultrasound test, TRUS : It is nowadays routinely performed when assessing the
status of the prostate. With an ultrasound probe a urologist can visualize the prostate through
the rectum wall, estimate the size of the prostate, assess the homogeneity of the parenchyma,
and observe possible cancer growth through the capsule of the prostate. The benefits of TRUS
are minimal invasiveness, relatively low cost and the fact that no ionizing radiation is needed.
The sensitivity of conventional TRUS has been estimated at 39%−75% and specificity at
40%−82% (Heijmink et al., 2011).
Positive results in all the tests above described are taken as signals of a possible presence of
prostate cancer, but in none of them can be taken as conclusive. The only reliable way to diagnose
a prostate cancer necessarily involves performing a biopsy test. From the biopsy result, the doctor
can determine whether there is cancer present, its aggressiveness and the likelihood of spreading.
Thus, only a biopsy can definitively diagnose prostate cancer.
If the initial tests (PSA level, rectal examination or ultrasound test) show that there is a possibility
of prostate cancer, a man may be offered a biopsy, in which several samples of tissue (usually
around 10) are taken from the prostate to be looked at under a microscope. Most centers used a
PSA cut-off value of 3.0 ng per milliliter as an indication for biopsy. Choosing a threshold serum
level in a screening setting will thus be a trade off between sensitivity and specificity.
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2.1.2 Prostate cancer screening
With an estimated 258 100 deaths, worldwide in 2008, prostate cancer is the sixth leading cause of
death from cancer in men, representing the 6.1% of the total (Ferlay et al., 2010). Comprehensibly,
with so many peoples’ lives affected by this disease, early detection has become the aim of many
center researchers, although it has become extensively discussed. Screening for disease in asymp-
tomatic individuals has an intuitive interest. If all cancers have a progression toward mortality,
then the best strategy seems to stop the progress of the disease as early as possible.
Screening, in medicine, is a strategy used in a population to identify a specific disease in those
individuals without signs or symptoms. This can include individuals with pre-symptomatic or
unrecognized symptomatic disease. As such, screening tests are somewhat unique in that they are
performed on persons apparently in good health. In particular, many studies apply the called “mass
screening”, which means the screening of a whole population or a subgroup, so that a particular
test is offered to each individual, irrespective of the risk status of the individual. Examples of
diseases in which mass screening techniques are applied can be breast cancer or cervix cancer.
In the case of prostate cancer, there are different tests used, but the main is the PSA level test (in
recent years accompanied by a PSARAT measurement), which defines the concentration of this
molecule in the blood. Other alternative tests are basically based on a physical examination: DRE
and TRUS tests.
The main sources of information that currently can be found about prostate cancer screening are the
reports on the two world’s important studies on the subject: the European Randomized Screening
for Prostate Cancer study (Schro¨der et al., 2012), hereafter the ERSPC, involving 182 000 men
aged 45 to 75 years from 8 participating countries, and the American Prostate, Lung, Colorectal
and Ovary Cancer Screening Trial (Andriole et al., 2009), PLCO, with 76 000 men aged 55–74 from
10 USA participating centers. The characteristics of ERSPC and PLCO studies were similar if not
identical. Thus, both of the studies had the objective of evaluating the effect of PSA screening on
death rates from prostate cancer.
However, much of the controversy regarding the efficacy of prostate cancer screening was originated
due to the divergence between the conclusions of these two studies. The European study showed
a reduced death rate ratio in the screening group compared to the control of 0.8 (95% confidence
interval 0.65−0.98), i.e., it concluded that screening reduced mortality by 20%. In contrast, the
American data showed no statistically significant difference in death rates between the screened
and control group, but there were more prostate cancer deaths in the screened group compared to
the control. Consequently, only the European trial suggested that there is a benefit in prostate
cancer mortality due to early detection and treatment.
Such divergences in the two studies results contributed to that currently there is not a global
agreement in effectiveness of prostate cancer screening. Moreover, recent studies (Chou et al.,
2011; Carter et al., 2013) are increasingly focusing on the possible adverse effects of treatment for
prostate cancer, which were reported in none of the mentioned studies. These adverse effects need
to be balanced against any potential reductions in mortality.
Hence, organizations such as the European Association of Urology (EAU), or the United States
Preventive Services Task Force (USPSTF), have advised against introducing a mass screening
programme for prostate cancer, after a review revealed that the harms involved with using the
PSA test to screen for the disease would outweigh the benefits. This decision was motivated by the
fact that PSA test by itself is not a highly sensitive test, so that we are unable to correctly identify
those cancers which will progress and those which are indolent and may be safely watched without
treatment.
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All these facts explain why the governments do not apply population programs for early detection
of the prostate cancer. However, although the benefits of screening are not at all clear, recent trends
indicate that screening may be a valid methodology provided that there exists a physician–patient
relationship that allows to understand the harms and potential benefits. In this line, (Moyer, 2012)
admitted the existence of a very small potential benefit, so it encouraged clinicians to screen only
the men who previously had been informed about the known risk of harms. This recommendation
is framed within the current trend towards more personalized medicine, taking the peculiarities of
each patient into account.
2.2 European Randomized Screening for Prostate Cancer: ERSPC study
2.2.1 Motivations and aims of the ERSPC
In recent decades, there have been many medical studies focused on the development and imple-
mentation of statistical techniques aimed at identifying the most critical covariates in the diagnosis
of a particular disease, with great emphasis on oncological diseases. Thereby, the interest in pre-
dicting the risk of cancer is part of the current personalization trend of medical interventions, which
in this case focuses on early disease detection through a screening process.
As already mentioned in the previous section, we can found some evidences showing that screening
for certain cancers can reduce mortality and improve patients’ quality of life. Screening can also
cause side effects in the healthy population in terms of false positive or false negative results, as
well as problems related to overdiagnosis. The problem basically consists of diagnosting cancers
(with all that implies in treatment terms) in individuals who would otherwise have died of natural
causes without a clinical diagnosis of cancer.
Thus, it is essential to reduce the enormous costs, both personal and financial, resulting from
incorrect treatment of the subject. To do this, it is necessary a further deepening of the statistical
treatment of such data, developing and implementing new models to improve cancer prediction
before symptoms. In this direction, the most scientifically valid way to assess the effect of early
detection of disease is still by means of a randomized controlled trial with death caused by the
disease as the main endpoint.
Among the contributions made in improving prediction of oncologic diseases, prostate cancer is a
disease whose early diagnosis may contribute to reduce the mortality rate. In this specific task,
in the early 1990’s began the aforementioned ERSPC project. It is a large randomized trial of
screening for prostate cancer, consisting of comparing an intervention arm (men to whom regular
PSA screening is offered), with a control arm (men to whom such screening process is not done).
The general goal of the ERSPC trial was to evaluate whether prostate cancer screening reduces
mortality from this disease in the asymptomatic population, within the scope of the different
countries of the European Random Screening for Prostate Cancer study, (ERSPC). Consequently,
ERSPC represented a survival study in which the event of interest was death caused
by prostate cancer (Schro¨der et al., 2012).
The particular aims of this study were the following:
1. Assess the extent to which false-positive screening results occurred in repeated prostate cancer
screening in the whole ERSPC trial.
2. Determine the possible risk for future prostate cancer, another false-positive screening result
and subsequent non-compliance in screening in men with false-positive screening results.
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3. Establish how screening affects the prostate cancer incidence (especially advanced cancer) in
Europe.
4. Determine how screening affects prostate cancer mortality in Europe, and which factors con-
tribute most to the group of screening failures (i.e. men who die of prostate cancer in spite of
screening).
2.2.2 Recruitment, randomization and protocol in the ERSPC
Pilot studies in Belgium and the Netherlands (the first participating centers of ERSPC) were
conducted between 1991 and 1994 and the results were reported. The conduct of similar pilot
studies became a condition for the admission of other European centers that joined the ERSPC in
subsequent years. Actually, the ERSPC study consists of seven countries having a sufficiently long
time monitoring: Belgium, Finland, Italy, Netherlands, Spain, Sweden and Switzerland (France
joined up to study in 2003).
Recruitment and randomization procedures differed among the study countries, having been de-
veloped in accordance with national regulations. On one hand, in Finland, Sweden, and Italy,
the trial subjects were identified from population registries and underwent randomization before
written informed consent was provided (population-based effectiveness trial). On the other hand,
the target population of Belgium, the Netherlands, Spain and Switzerland was also identified from
population lists, but when the men were invited to participate in the trial, only those who provided
consent underwent randomization (efficacy trial).
The seven original participating countries in ERSPC trial and the specific characteristics of each
study section are illustrated in Table 2.1.
Country Recruitment
Age at
Entry (yr)
Screening
Began
Interval
(yr)
PSA cut-off
(ng/ml)
Belgium Volunteer 50−74 1991−2003 4−7 PSA ≥10 (1992−1994)
PSA ≥4 (1995−1997)
PSA ≥3 (from 1997)
Finland Population 55−67 1996−1999 4 PSA ≥4
Italy Population 55−71 1996−2000 4 PSA ≥4
Netherlands Volunteer 55−75 1991−1999 4 PSA ≥4 (1991−1997)
PSA ≥3 (from 1997)
Spain Volunteer 45−71 1996−1999 4 PSA ≥4 (1996−1998)
PSA ≥3 (from 1998)
Sweden Population 50−66 1994 2 PSA ≥4
Switzerland Volunteer 55−70 1998−2003 4 PSA ≥3
∗ French data are not included
Table 2.1. Characteristics of the screening protocols of the seven older ERSPC members (Adapted
from ERSPC Conclusions, Schro¨der et al. (2012).
In the screening arm, tests were performed every 4 years with the exceptions of Sweden, where
rescreening took place after 2 years, and Finland, with exceptional rounds of 7 years during certain
period. In all cases, therapy started when cancer was detected. In contrast, in the control arm no
tests were performed.
At the beginning of 2004, the study had recruited a total of 182 160 asymptomatic men, aged
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45−75 years and distributed among the following seven countries: Belgium, Finland, Italy, The
Netherlands, Spain, Sweden and Switzerland. With all these countries taking part in this project,
it became the world’s largest prostate cancer screening.
From the total number of recruited men among the seven chosen countries, 160 died during ran-
domization process, finally remaining a total of 182 000 men. Their distribution among countries
is displayed in Table 2.2.
Country Men Recruited
Randomization
Screening Arm Control Arm
Belgium 9980 5000 4980
Finland 80458 32000 42458
Italy 14557 7286 7271
Netherlands 42376 21210 21166
Spain 4278 2416 1862
Sweden 19946 9973 9973
Switzerland 10405 4931 5475
Total 182000 82816 99184
∗ French data are not included
Table 2.2. Recruited men in the first seven ERSPC members (Adapted from ERSPC Conclusions,
Schro¨der et al. (2012)).
These recruited men were divided between screening and control groups as showed in Figure 2.2:
a) 82 816 men were assigned to screening arm, of whom 82% had at least one PSA test during
trial.
b) 99 184 men were assigned to the control group. Based on single site, screening in controls
estimated at approximately 20%.
182000 Subjects 45-75 years old
underwent randomization
82816 Were assigned to the
screening arm
6830 Men were diagnosed
with prostate cancer
99184 Were assigned to the
control arm
4781 Men were diagnosed
with prostate cancer
Figure 2.2. Enrollment and outcomes according to age group at randomization (Adapted from Schro¨der
et al. (2012))
2.2.3 General conclusions of the ERSPC
In both arms, similar prostate cancer cases were treated similarly. After a mean follow-up of more
than 10 years, in the screening group 6830 individuals were diagnosed with prostate cancer, whereas
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in the control group were diagnosed 4781 cases (Schro¨der et al., 2012). These data are unlikely to
help to clarify the debate over the value of mass screening for prostate cancer. From one point of
view, one could use them to argue that screening can prevent between 20 and 30 percent of prostate
cancer-specific deaths with only 9 years of follow-up. From the alternative point of view, one could
argue that screening a million men would indeed prevent about 950 prostate cancer-specific deaths,
but would also lead to the potential over-treatment of 36 out of every 37 cases of prostate cancer
identified, and would have no impact whatsoever on overall mortality (Roobol et al., 2012).
In general, prostate cancer screening has remained controversial because it has also led to consid-
erable false positive results and extensive overdiagnosis of disease that would not otherwise emerge
clinically. In the case of the two large studies cited, ERSPC trial revealed a significant reduction
in the rate of death from prostate cancer (relative reduction, 20%) among men offered screening
for prostate-specific antigen. In contrast, the American PLCO, did not show an effect of screening
on prostate cancer mortality. Furthermore, the critics of screening programs argue that in ERSPC
project, the benefit of screening is associated with an unacceptably large proportion of overdiagno-
sis and potential overtreatment. This divergence of results leads to the fact that screening utility is
still under scientific discussion, indicating that shared decision making is necessary prior to testing
and taking prostate biopsies.
2.3 The Spanish section of the ERSPC
2.3.1 Development of the ERSPC Spanish section
The study population in the ERSPC Spanish branch (Berenguer et al., 2003; Luja´n et al., 2012)
comprises men recruited from two cities, Getafe and Parla, located at the 10th Health Area from
Comunidad de Madrid. After a mailed invitation to 18612 men of the referred health zone, the
Spanish section finally enrolled 4278 individuals between February 1996 and June 1999 (participa-
tion rate of 23%). At the time of randomization, these men were 45 to 71 years old and had a life
expectancy greater than 10 years. Although randomization was then made 1:1 to either screening
(tests with PSA) or control group (no tests), the number of subjects recruited was different in
both arms due to some initial quirks in the recruitment process (by decision of the Quality Control
group, there were suppressed those control arm subjects who were not finally invited). For this
reason, among the 4278 men who were recruited, 2416 subjects were assigned to the screening arm
and the remaining 1862 to the control arm.
Year Men Invited Men Accepted
Randomization
Screening Arm Control Arm
1996 1190 268 (23%) 124 144
1997 4036 1124 (28%) 850 274
1998 11372 2684 (24%) 1344 1340
1999 2014 202 (10%) 98 104
Total 18612 4278 (23%) 2416 1862
Table 2.3. Recruited population by year in ERSPC Spanish section (Berenguer et al., 2003).
The database of the ERSPC Spanish section included several variables like subject identifier, date
of birth, date of randomization, arm of study (screening or control), dates of attendance (PSA
testing), biopsy result or prostate cancer detection. In both arms, annual mortality was studied
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and cause of death recorded thanks to the agreement reached with the Spanish Institute of Statistics
(providing the date of death and its underlying cause, as stated in the death certificate).
During the study it was performed a follow-up of the screening arm subjects, recommending a
biopsy based on the only criterion of the serum PSA level registered in a visit of the individual.
In particular, biopsies were indicated when PSA level was above a pre-specified threshold, and if
the result was negative then men were invited to a new re-screening round after a year interval
(“early recall”). However, if the PSA level was considered normal, the standard interval to the next
screening round (“routine recall”) was 4 years. In contrast, no tests were applied in men allocated
to the control group.
Subjects in the screening group have a variable number of visits. In each visit the patient’s total
PSA level evolution was recorded, and from 2002 onwards, it was also registered the free PSA
(FPSA, ng/ml) and PSA ratio (defined as PSARAT = FPSA/PSA). Furthermore, on some
dates distributed throughout the study patients also had a digital rectal examination (DRE ) and
an ultrasound rectal test (TRUS ). However, no biopsy was indicated based on DRE or TRUS
findings.
In the screening group, PSA thresholds for which the study recommended the biopsy varied over
time, distinguishing three periods:
1. First protocol: From February 1996 to April 1998:
Biopsy prescription for those individuals with a PSA > 4 ng/ml, and in the case of negative
result the patients were called to an early recall visit on a time period under two years. Moreover,
the protocol also established that if PSA level recorded during a visit was such that 3 ng/ml
≤ PSA ≤ 4 ng/ml, then a biopsy test was not prescribed but the patient was called for a new
visit within 2 years.
2. Second protocol: From May 1998 to December 2001
Biopsy indicated to anyone who registered PSA ≥ 3 ng/ml. In the case of a negative result
on biopsy, the person would be called to an early recall (always within less than two years),
undergoing further evaluation (“rescreen”) that included a new determination of PSA (and
indicating again a biopsy if PSA level exceeded the allowable threshold).
3. Third protocol: From January 2002 to October 2005
The protocol used the same criterion as in the previous period plus a biopsy indication when
the total PSA was in the range 1−2.99 ng/mL and PSARAT ≤ 0.20.
First visits with PSA readings took place on 19th February 1996, and from that date began a
three-year period of first visits that lasted until 30th June 1999. Hence, the screening group men
must have his first visit located within this three-year period. Last visits with PSA measurements
occurred in October 2005, and the database includes active surveillance of prostate cancer incidence
until 31/12/2007.
Accordingly with the above information, the study started at 19th February 1996, and
the finalization of active surveillance on prostate cancer incidence took place on 31st
December 2007.
2.3.2 Specific results for the ERSPC Spanish section
There were recruited 2416 subjects in the screening arm and 1862 in the control. As indicated by
Luja´n et al. (2012), their average age was 57.8 years and the median follow-up period 13.3 years. At
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the end of follow-up were recorded a total of 427 deaths (the event of interest in ERSPC project),
of which 9 were related to prostate cancer.
Regarding the causes of death, the main cause was due to malignant tumors (52.9%), highlight-
ing the lung (15.9%) and colorectal cancer (7.0%). Secondly, cardiovascular diseases(17.3%) and
respiratory incidences (8.9%). In addition, no differences were observed in the distribution of the
causes of death between the control and screening (p-value = 0.20).
Survival analysis (consisting of non parametric estimation) was used to compare mortality rates
between screening and control groups during the 15-year period of the study, and a log-rank test
was performed between survival estimated curves. The results indicated no significant differences
between the two arms with a highly evidence that led to not rejecting the null hypothesis (p-value =
0.94). In the same line, there was no significant effect between arms when performing a comparison
based on mortality rates due to different cancer types (p-value = 0.54).
Thus, the study results indicated that we could not establish differences in mortality after 15 years
of follow-up. However, the prostate cancer mortality in the population at the end of this period
was very limited (less than 1%).
2.4 Source dataset of the cohort under study
2.4.1 Source dataset: The Prostate Cancer (PCa) Dataset
The aim of this section is to introduce the dataset that has motivated the different methodologies
applied in this research work. In particular, information derived from ERSPC Spanish section has
been used, keeping in mind all variables which are expected to have effect during the different
analyses. The database was called the PCa Dataset.
Our source dataset has been configured to give an exhaustive picture of all data provided by the
ERSPC Spanish branch, despite that the PCa Dataset compiles information which has not been
directly used in the subsequent chapters of this work research, either because a lack of longitudinal
follow-up or because the need of implementing other more advanced methodologies.
Our study will focus specially in the subject’s PSA level at their respective time points, because
this biomarker is present in each of the records and is the main parameter to recommend if the
patient should undergo a biopsy test. As already mentioned before, a biopsy test is ultimately the
gold standard to establish whether there is a diagnosis of prostate cancer.
2.4.2 The double target in PCa Dataset configuration
The PCa Dataset allows to model the given information from a simultaneous dual approach:
• Survival approach: The PCa Dataset contains the follow-up time from the first visit of each
subject until the possible detection of prostate cancer. This information allows to determine the
observed survival time from the birth date of each subject up to the mentioned event, relating
the event time outcome to the time-dependent covariates in the studio. In contrast with the
ERSPC study, where the time until subject’s death by prostate cancer was analyzed, in our
study the event of interest, E, is defined as the diagnosis of prostate cancer.
• Longitudinal approach: Secondly, it must be taken into account that both the true importance of
a biomarker in describing prostate cancer progression and its association with survival time can
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only be revealed when repeated measurements of the marker are considered in the analysis. For
this reason, the PCa Dataset was also constructed in order to carry out a longitudinal
study of different time-dependent covariates associated with each subject, allowing us
to establish the temporal relationship between them and with respect to the particular event of
interest.
Both commented approaches are different but complementary. The ultimate goal is to obtain
a dataset in a way that allows us merging both survival and longitudinal processes into a one
statistical model, giving rise to the so-called joint models, JM. Such models allow to establish the
association between a longitudinal biomarker and time until some specific event occurs.
2.4.3 Information provided by the PCa Dataset
The PCa Dataset included the 2416 subjects assigned to the screening arm of the Spanish section
ERSPC study. One individual from the screening arm was removed from the dataset for having
had a previous cancer, so we finally had information in our PCa Dataset on 2415 men,
representing 4673 visits which are unequally distributed among them.
For each subject, the individual profile description covered from his first visit date until the date
on which the first of these three possible scenarios happens:
• Scenario 1: The subject profile reached the study end, on 31/12/2007, without being diagnosed
with prostate cancer, that is, without having developed the disease.
• Scenario 2: The subject profile ended at the date of his death, prior to 31/12/2007. Although in
this case the individual did not achieve the end of the study, he did not experience the disease
during the study.
• Scenario 3: The subject profile ended at the date of his prostate cancer diagnosis, prior to
31/12/2007. In this case the individual developed the disease within the study.
In considering the three scenarios described above, it is clear that the treatment of the data must
be different depending on the case. In particular, in either of the first two scenarios the individual
did not experience the event of interest, while in the the third scenario the profile of the individual
did reach this event. Consequently, in the first two cases we could only say that up to a determined
time point, the subjects survived the disease occurrence, but we had not more information beyond
that date.
The statistical inference with survival data is usually complicated by presence of these incomplete
observations. This distinction has its origin in the phenomenon known as right-censoring data,
consisting of some individuals not experiencing the event of interest when they reached the closing
date of the study or dropping out of the study before reaching that date. The analytic treatment
of right-censored data and its implications will be discussed in detail in the next chapter.
Once the general casuistry was defined, the interest lied in able to define a dataset that allowed not
only good survival characterization, but also a longitudinal one. Among many other variables that
were collected in the Spanish Section of ERSPC study, the following 16 variables were included in
the PCa Dataset:
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Name Description
OBS Row identification
ID Subject identifier
RANDAT Date of randomization
DATE Date of record
RECTYP Type of record, categorized for each observation according to the code:
0: Observation associated with a record date that refers neither to a trial
exclusion of the subject nor at the time of his death.
1: Observation associated with a record date of exclusion from the study of
the subject. The “exclusion” means that the subject has not been invited to
further re-screening, but the study has continued to gather information on
his potential prostate cancer incidence until 31/12/2007.
2: Observation associated with the death date of the patient, which means
that the subject has died before 31/12/2007.
AGE Age of the patient at each of his record dates (years). The age was obtained
in days and divided by 365.25
PSA Total level of prostate-specific antigen (ng/ml)
DRE Information available on digital rectal examination
0 = Not performed, 1 = Negative, 2 = Positive, NA = Unknown
TRUS Information available on transrectal ultrasound test
0 = Not performed, 1 = Negative, 2 = Positive, NA = Unknown
TIME Observation time (years), which may correspond to an event or to a right-
censored data.
CENS Censoring indicator, categorized for each subject according to the code:
0 = Right-censored, 1 = Event
BIOPSY Biopsy result, categorized for each observation according to the code:
0 = Not recommended, 1 = Not performed but recommended,
2 = Negative result, 3 = Positive result: Screening prostate cancer diagnosed,
NA = Unknown
FPSA Free PSA level (ng/ml).
Result = real positive number (0.nn) , NA = Unknown
PSARAT PSA ratio, defined by PSARAT = FPSA/PSA (range between 0 and 1).
Result = real positive number (0.nn), NA = Unknown
CANTYP Type of cancer, categorized for each subject according to the code:
0 = Not tumor, 1 = Screen-detected cancer,
2 = Interval cancer, NA = Unknown
GLE2 Gleason grading system, which is measured in a 1−3 scale, obtained for each
subject by rescaling (according to the ERSPC criteria) the Gleason results
(1−10).
If Gleason = 0 then GLE2 = 0: Not performed (no tumor)
If Gleason in 1−4 then GLE2 = 1: Low aggressiveness level
If Gleason in 5−7 then GLE2 = 2: Medium aggressiveness level
If Gleason in 8−10 then GLE2 = 3: High aggressiveness level
If Gleason = NA then GLE2 = NA: Missing value (unknown)
Table 2.4. Names and description of the variables in the PCa Dataset.
Due to the time depending covariates on a given subject, the data was arranged in the so-called
long format, in which the measurements of each individual are stored in multiple lines. Thus, the
PCa Dataset contains in this long format both the survival and the longitudinal information of
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each subject.
ERSPC Database
Data from 7 countries
ERSPC Spanish section
4278 Men recruited
PCa Dataset
2415 Subjects
4673 Visits
16 Variables
Figure 2.3. Obtainment of the PCa Dataset from the ERSPC Spanish branch data.
Table 2.5 displays the format and the structure of the PCa Dataset, and more information can be
found in Appendix 1.
ID RANDAT DATE RECTYP AGE PSA DRE TRUS BIOPSY FPSA PSARAT TIME CENS CANTYP GLE2
1 16/04/1996 26/04/1996 0 54.09 0.70 0 0 0 NA NA 65.77 0 0 0
1 16/04/1996 25/10/2000 0 58.59 0.60 0 0 0 NA NA 65.77 0 0 0
1 16/04/1996 25/02/2004 0 61.92 0.68 0 0 0 NA NA 65.77 0 0 0
9 03/01/1998 03/02/1998 0 54.86 0.70 0 0 0 NA NA 64.77 0 0 0
10 05/04/1996 15/04/1996 0 53.06 0.20 0 0 0 NA NA 64.77 0 0 0
10 05/04/1996 03/10/2000 0 57.53 0.10 0 0 0 NA NA 64.77 0 0 0
10 05/04/1996 24/02/2004 0 60.92 0.19 0 0 0 NA NA 64.77 0 0 0
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
9478 23/06/1999 23/06/1999 0 55.30 0.00 0 0 0 NA NA 63.82 0 0 0
9478 23/06/1999 24/10/2003 0 59.64 0.69 0 0 0 NA NA 63.82 0 0 0
Table 2.5. Layout information in PCa Dataset.
2.4.4 Description of the PCa Dataset
Study duration
The study began on 19th February 1996 (visit date of the first men to join the study) and ended,
due to administrative reasons, on 31st December 2007. The period of time between two dates is
called observation window or sometimes time window, and corresponds to the time period when it
was performed an active surveillance of the 2415 dataset subjects.
Longitudinal characterization
The PCa Dataset contains 2415 individuals aged 45−71 years from the screening arm of the ERSPC
Spanish section. In Figure 2.4 is displayed how the mean age at randomization process, conducted
during the first three years of the study, was 57.72 years and the standard error 5.45 years (Luja´n
et al., 2012).
The range of follow-up in time was 0.00−11.86 years, with a mean of 9.28 years and a median of 9.73
years. At this point, it must be noted the limited longitudinal monitoring of the data, as evidenced
by the fact that the average number of records by subject is about two measurements (Table 2.6).
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Figure 2.4. Age of 2415 subjects at their randomization date in the ERSPC Spanish section (Luja´n
et al., 2012).
This fact had imposed a logic limitation in getting a more precise characterization of individual
trajectories, and must be taken into account when interpreting the study results. However, the
small number of time points for each individual does not mean that the obtained results obtained
are wrong: simply the results accuracy would increase with a greater number of records by subject.
Distribution of the number of visits
Subjects with 1 visit 573 (23.7%)
Subjects with 2 visits 1499 (62.1%)
Subjects with 3 visits 293 (12.1%)
Subjects with ≥ 4 visits 50 (2.1%)
Average number of visits per subject 1.9
Table 2.6. Distribution of the number of visits among the 2415 subjects in the PCa Dataset.
Information about explanatory covariates
As previous commented, visit study’s principal covariate is the PSA level in each visit. Serum PSA
determinations were mostly performed at an interval of 4 years. A biopsy was indicated if PSA ≥ 3
ng/ml, and in case of a negative result the subject was recalled for an early visit within a 2 years
period. Globally, among the 2415 participants, a total of 4673 follow-up PSA measurements at the
successive screening visits have been recorded. Last visits with PSA readings in the study took
place in October 2005, and the survey data include active surveillance of prostate cancer incidence
until 31st December 2007, not taking into account any collected information about the subjects
occurred after that date.
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Concerning the number of visits per subject, data are not balanced because individuals do not
enter the study at the same age. Table 2.7 shows the distribution of subjects according with the
number of visits and a descriptive statistics of the subjects’ PSA mean measurements for each one
of the categories and the overall sample, as well as the frequency and percentage of prostate cancer
diagnosed subjects. In this regard, we can remark the following important results: a) the subset
of men with two PSA measurements is the most frequent (62.1%), b) there is 23.7% of subjects
that they are contributing to the analysis with only one PSA observation, scarcely nourishing the
longitudinal analysis, c)this group with only one visit contains individuals with a huge variability
of PSA level (StDev = 5.67 ng/ml and Max = 69.80 ng/ml), and d) categories with one or two
visits concentrate the main proportion of PCa diagnosed cases (87.1%).
Number of visits per subject
1 2 3 ≥ 4 Overall
Sample size (%) 573 (23.7) 1499 (62.1) 293 (12.1) 50 (2.1) 2415 (100.0)
PSA descriptive
Mean 2.40 1.40 1.92 5.46 1.78
StDev 5.67 1.67 2.25 2.79 3.20
Min 0.00 0.00 0.00 0.50 0.00
1st Q 0.60 0.60 0.60 3.79 0.63
Median 1.10 1.00 1.10 4.69 1.06
3rd Q 2.20 1.67 2.44 6.28 1.95
Max 68.90 42.30 20.36 15.53 68.90
PCa diagnosed (%) 51 (44.0) 50 (43.1) 13 (11.2) 2 (1.7) 116 (100.0)
Table 2.7. Distribution of the subjects, descriptive statistics of the PSA measurements and distribution
of the prostate cancer diagnosed cases, stratified by the number of visits and overall.
On the other hand, the results for categorical covariates DRE and TRUS were also collected at
each individual’s visits, which in the PCa Dataset play the role of auxiliary variables that help to
calibrate PSA effect on prostate cancer risk.
Table 2.8 presents a descriptive summary of PSA levels stratified by combined DRE and TRUS
categories:
DRE TRUS Visits Subjects Events Subj./Ev.(%)
PSA Summary
Mean sd Min 1stQ Med 3rdQ Max
0 0 3999 2300 14 0.61 1.26 1.46 0.00 0.59 0.90 1.50 47.00
0 1 16 16 1 6.25 3.96 1.37 1.19 3.18 3.67 4.20 7.12
0 2 1 1 0 0.00 14.00 – 14.00 14.00 14.00 14.00 14.00
1 0 45 45 6 13.33 4.13 3.51 1.05 1.70 3.50 5.00 19.30
1 1 500 382 60 15.71 4.55 3.41 1.00 3.00 4.07 5.40 51.60
1 2 33 32 14 43.75 7.67 4.50 1.60 4.40 6.00 9.40 21.70
2 0 12 12 2 16.67 2.86 1.42 1.25 1.80 2.77 3.65 6.10
2 1 40 37 8 21.62 5.70 3.51 1.19 3.20 4.33 7.20 13.20
2 2 27 26 11 42.31 14.86 18.86 1.71 3.90 5.60 13.90 68.90
Table 2.8. Distribution of the subjects, descriptive statistics of PSA measurements and distribution
of the PCa diagnosed cases, stratified by DRE and TRUS values at each of the 4673 visit dates.
The above table displays that most observations correspond to the pair (DRE = 0 ; TRUS =
0), so not performed tests represent a total of 85.6% over 4673 recorded time points. It is also
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interesting to note that 2300 subjects had at least one PSA level measurement associated with this
pair. Considering the informative character of the two auxiliary covariates (the zero value can be
associated to a low risk PSA level), it can be concluded that most of the studied subjects will move
around low PSA values, having therefore a low risk of developing prostate cancer.
High right-censored data proportion
At the end of follow-up 116 (4.8%) prostate cancers were diagnosed, while the remaining 2299
(95.2%) subjects led to right-censored data. This result is in agreement with the observations made
previously, showing that it is a disease with a low incidence rate over the total adult population.
However, the fact that the incidence is low does not imply that it is irrelevant. A percentage of
5% in cancer incidence during the window observation is high enough to be considered a detailed
study to identify what are those more important risk factors in the disease development. In this
regard, it would be desirable to have information about another important risk factors like family
history, prostate volume, etc.
2.4.5 Transformation of some variables from PCa Dataset
Double log-transformation of PSA variable: LLPSA
In the health research studies, many of the most classical biomarkers are continuous variables that
have heavily skewed distributions, with long right tails. We can have one or a few values which
are much larger than the vast majority of the data, so that these high values make frequently very
difficult to identify the structure in the rest of the data. Furthermore, these kind of variables are
not normally distributed, and therefore do not satisfy the required assumptions to apply neither
certain linear models nor parametric statistical tests.
In connection with the above paragraph, the PSA biomarker is a clear example of biological variable
with high skewed distribution. In particular, its values stand typically under 5 ng/ml, but can be
placed above 50 ng/ml (outliers at the high end). In our study, the PSA ranged from 0.00 to
68.90 ng/ml with mean and median values 1.78 and 1.06 ng/ml., respectively (Table 2.7). There is
therefore a need for a mathematical transformation of PSA values to avoid masking the structure
presented by smallest values.
Considering the longitudinal character of the PSA variable, the change experienced in applying
successive logarithmic transformations should be undertaken at a given time point. Moreover, it
must be taken into account that not every men have the same number of visits (and therefore
of measurements), and each of them contributes with different time points. It was consequently
decided to use the PSA value at their respective first visits as a common reference point, then
assimilating that measurement to a basal value denoted by PSA0.
To accommodate for data normality, it was originally considered a non linear transformation based
on application of a logarithmic scale. Therefore, larger values moved closer together while smaller
values stretched out, and the original values reduced to a more manageable size. We also had to
take into account the presence of null values, so we decided to add a constant k = 1 as proposed
in Slate and Turnbull (2000), so in our case: LPSA0 = log(1 + PSA0). However, the dispersion of
our PSA measurement values was so high that a double logarithmic transformed scale was needed:
LLPSA0 = log{1 + log(1 + PSA0)}.
As showed in Figure 2.5, the successive log-transformations of PSA variable make positively skewed
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distribution more normal. In the original scale, the data are long-tailed to the right, but after a
double logarithmic transformation is applied, the data distribution tends to be symmetric.
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Figure 2.5. (a) Original PSA0 data histogram, (b) PSA0 data histogram after first log-transformation:
LPSA0 data, and (c) PSA0 data histogram after double log-transformation: LLPSA0 data.
Hence, the main variable used in this prostate cancer study has been LLPSA, defined
as:
LLPSAij = log{1 + log(1 + PSAij)} (2.1)
for the i−th subject, i = 1, . . . , 2415, at tij time point, j = 1, . . . , ni
Translation of the starting point
It is important to note that all men in the study were at least 45 years old at the time of first
visit. In order to avoid working with a long period of time without data, we opted to apply a 45
years-translation, and considered 45 years as the initial time point:
AGE
′
ij = AGEij − 45
TIME
′
ij = TIMEij − 45
(2.2)
for the i−th subject, i = 1, . . . , 2415, at his tij time point, j = 1, . . . , ni
Relation between the LLPSA and AGE covariates at first visit
Since time from study entry to prostate cancer diagnosis can vary depending on the age, it is
important to account for this issue.
Figure 2.6 displays LLPSA0 histrograms, stratified by tertiles of age at entry ([45; 55), [55; 60)
and ≥ 60 years), namely AGE0. We can realize that, when age increases, the LLPSA0 levels move
toward higher values.
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Figure 2.6. LLPSA0 data histogram for (a) 45 ≤ AGE0 < 55, (b) 55 ≤ AGE0 < 60, and (c)
AGE0 ≥ 60.
The existing interaction between both variables results in the need to analyze the normality of
LLPSA on the basis of its dependence on AGE. For this purpose, the first visit values were con-
sidered again as a baseline, so we worked in terms of LLPSA0 × AGE0. The assumption of a
normal model for a population of responses will be required in order to perform certain inference
procedures, and histograms could be used to get an idea of the shape of a distribution. However,
there are more sensitive tools, like the quantile-quantile plot test, commonly called q-q plot. In
general, the q-q plot goal is to verify the assumption of normality, comparing the distribution
of the sample to a normal distribution. The plot represents the quantiles of a standard normal
distribution against the corresponding quantiles of the observed data. If the observations follow
approximately a normal distribution, the resulting plot should be roughly a straight line with a
positive slope (consequently, deviations from this line would indicate possible departures from a
normal distribution).
Figure 2.7 presents the q-q plots associated to each 9 possible combinations according to the degree
of transformation of PSA0 values and stratifying by AGE0. This multi-panel q-q plot displays an
underlying normality as logarithmic are applied to PSA0 values. Thus, the q-q plots corresponding
to LLPSA0 show evidence of an approximately normal distribution except for some large outliers
which in any case do not change the general behavior.
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Figure 2.7. Normal quantile plots depending both on the PSA0 subject’s level and his respective
AGE0 tertile. The three left panels correspond to q-q plots of the untransformed PSA0 data, the middle
column panels contain the q-q plots for log-transformed data, and the three right panels are the q-q
plots for double log-transformed measurements. From the top row to the bottom row, the AGE0 tertile
increases.
CHAPTER 3
JOINT MODELING OF LONGITUDINAL AND SURVIVAL DATA
3.1 Motivations for Joint Modeling
Many current investigations generate both longitudinal measurement data, with repeated measure-
ments of a response variable at a specific number of time points, and time-to-event data, in which
times until a particular event are recorded. For example, in many medical studies, we often collect
patients’ information repeatedly over time, and we are also interested in the time to recovery or
recurrence of a disease. Separate analyses of longitudinal and survival data may lead to inefficient
or biased results, so it is necessary a jointly modeling in order to incorporate all information simul-
taneously and provide valid and efficient inferences. Such an approach is termed Joint Modeling.
Joint models of longitudinal and survival data have attracted increasing attention over the last
two decades. They were introduced during the 90’s (Tsiatis et al., 1995; Faucett and Thomas,
1996; Wulfsohn and Tsiatis, 1997) and since then have been applied to a great variety of studies
in epidemiological and biomedical areas. In turn, these studies have fed a wide methodological
research on the subject, with models focused on event times, longitudinal patterns or both. In this
sense, Tsiatis and Davidian (2004) provide excellent review up to date. More recently, Rizopoulos
has made a great contribution facilitating the use of the joint modeling methodology, first by means
of an excellent overview of the theory and applications of joint modeling (Rizopoulos, 2012b) and
secondly by developing the JM (Rizopoulos, 2010) and JMbayes (Rizopoulos, 2012a) R packages for
the frequentist and Bayesian approaches, respectively. In particular, computational applications
included in this work is based on Rizopoulos’ contributions.
A typical joint model setting is to assume a linear mixed effects model for the longitudinal covariates
and a Cox model or an accelerated failure time (AFT) model for the survival data, with the
two models sharing some random effects or covariates. Therefore, by joint modeling techniques
longitudinal measurements are adjusted to allow for non-ignorable missing data due to informative
dropout, which cannot be appropriately handled by the standard linear mixed effects models alone.
For this purpose, the likelihood method is often used, implemented by EM algorithms (Dempster
et al., 1977).
3.2 Longitudinal Data Analysis
3.2.1 General features of longitudinal data
Longitudinal studies are based on the data resulting from the measurements of subjects taken
repeteadly at multiple follow-up times, thereby allowing the direct study of changes in the response
variable within the duration of the study. Such data are frequently encountered in health sciences, in
which longitudinal studies play a prominent role in enhancing the understanding of the development
and persistence of a specific situation. The main characteristics of longitudinal studies are: 1) an
outcome is measured repeatedly within a set of units, 2) longitudinal data are clustered, so repeated
measures data are positive correlated within subjects and thus require special statistical techniques
for valid analysis and inference, 3) repeated measures obtained from a single subject allow to capture
21
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within-subject patterns of change, 4) the number of repeated observations and their time points
can vary widely from one subject to another, therefore having unbalanced longitudinal designs, and
5) missing data that arise when subjects drop out of the study can lead to biased estimates when
the probability of missingness is associated with the outcomes.
3.2.2 Sources of variability in longitudinal data
Between-subject variability
Between-subject variation reflects the variation of the mean of each measure from the population
mean. In any longitudinal study, some individuals consistently respond higher than the population
average, while others tend to respond below the referred average. Thereby, this variability is based
on the fact that each studied subject has an underlying behavior (due to genetic, environmental or
social factors), and its natural trend can be derived from all repeated measurements taken on.
Within-subject variability or residual variability
It measures the variability in response within the same subject, being sometimes referred as inherent
biological variability. This variation is based on the variability of scores around the subject’s
true and unobservable score, because a random measurement error is associated to each biological
outcome. Consequently, within-subject variability reflects the part of variance that can not be
explained by some predictor variable, given the random effects.
Figure 3.1. Conceptual representation of variation sources in case of balanced longitudinal design
with three subjects and five time points: 1) the thick solid line represents the average evolution, 2) the
dotted lines represent the pattern of error free responses for the subject over time, 3) the grey points
are the observations of these responses, which are subject to measurement error, and 4) the thin solid
lines are the trend line for each subject.
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3.2.3 The linear mixed effects model
Methodology for analysis of serial data over time
The main goal of linear mixed effects models is to account for the special features of serial evalua-
tions of clinical parameters over time, being able to stablish a plausible model in order to describe
the particular evolution of each subject included in a longitudinal design. The particular features
of these models are that they can work with unbalanced datasets (unequal number of follow-up
measurements between subjects and varying times between repeated measurements of each sub-
ject), and that they explicitly take into account that measurements from the same patient may be
more correlated than measurements from different patients.
The intuitive idea behind these models is described by Figure 3.2, where it is shown that a linear
mixed effects models must have 2 parts in order to describe separately the trend of each subject:
1. Fixed-effects part (solid line in Figure 3.2):
Describes the average evolution in time of a specific variable under study, where this average
is taken overall from the subjects in the sample at hand and is an estimate of the evolution of
the longitudinal covariates in the target population. Fixed effects assume that observations are
independent.
2. Random-effects part (dashed lines in Figure 3.2):
Describes the particular evolution in time for each of the subjects under study, taking into
account the data correlation within subjects.
Figure 3.2. Intuitive representation of a linear mixed effects model with two subjects. The points
represent hypothetical longitudinal responses for two subjects, and both of them have incomplete data
due to drop-out. The dashed lines are the respective subject-specific evolutions, while the solid line
defines the population trend.
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Generalization of the linear mixed model
Let consider a general longitudinal design with n subjects so that each of them has a different
number of ni repeated measurements of the response variable at different time points. Let denote
yij the response variable on the i−th subject, i = 1, . . . , n, observed at time point tij , j = 1, . . . , ni,
where the outcome is linearly related to a set of p explanatory covariates and q random effects
(q ≤ p + 1). Thus, the set of repeated outcomes for the i−th subject can be expressed as the
ni−dimensional vector, yi = (yi1, yi2, . . . , yini)T.
Assuming that the longitudinal outcomes are normally distributed, the general linear mixed model
uses the following matrix and vector notation for the i−th individual (Laird and Ware, 1982;
Verbeke and Molenberghs, 2000):

yi = Xiβ + Zibi + εi
bi ∼ Nq(0,D)
εi ∼ Nni(0, σ2Ini)
(3.1)
where Xi and Zi are respectively the ni × (p + 1) and ni × q design matrices for fixed and ran-
dom effects, β denotes the (p + 1)−dimensional vector for the p + 1 unknown fixed effects, bi
is the q−dimensional vector for the considered random effects in the model, D is the q × q co-
variance matrix for random effects and εi is the random error ni−dimensional vector, where σ2
represents the within-subject variation (constant across the subjects). In addition, random effects,
{b1, b2, . . . ,bn} are assumed to be independent of error terms, i.e., {ε1, ε2, . . . , εn}.
The above linear mixed model expression can be reformulated in order to describe the subject-
specific evolutions at any time t:

yi(t) = x
T
i (t)β + z
T
i (t)bi + εi(t)
bi ∼ Nq(0,D)
εi(t) ∼ N (0, σ2)
(3.2)
where xTi (t) and z
T
i (t) denote row vectors of the design matrices for the fixed and random effects,
respectively.
The interpretation of the p + 1 fixed effects coefficients, β = (β0, β1, . . . , βp)
T, is exactly the same
as in a simple linear regression model, while the coefficients of the random effects q−dimensional
vector for subject i, bi, are interpreted in terms of how a subset of the regression parameters for
the i−th subject deviates from those in the population.
Estimation of linear mixed model parameters
Under the assumption that bi and εi are independently distributed as multivariate normal, the
estimation of the parameters is based on maximum likelihood inference. In particular, the marginal
density of the observed data for the i−th subject is given by
p(yi) =
∫
bi
p(yi|bi)p(bi)dbi (3.3)
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and the above integral leads to the closed-form solution yi ∼ N (Xiβ,Vi), where Vi = ZiDZTi +
σ2Ini . The variance-covariance matrix can be estimated using the theory of restricted maximum
likelihood, REML (Harville, 1977), which is usually preferred to ML because it produces estimators
with less bias (Schabenberger and Pierce, 2002). The idea behind REML is to separate the part of
the data used in the estimation of Vi from the part used in the estimation of β. In general, Vˆi can
not be written in a closed form, so an iterative algorithm is necessary (e.g. Lindstrom and Bates,
1988).
If we know the REML estimation of Vi, the coefficients of the fixed effects vector are estimated by
the usual generalized least squares estimator
βˆ =
(
n∑
i=1
XTi Vˆ
−1
i Xi
)−1 n∑
i=1
XTi Vˆ
−1
i yi . (3.4)
Standard error for the fixed effects coefficients can be obtained by calculating the variance of the
above estimator:
V̂ar(βˆ) =
(
n∑
i=1
XTi Vˆ
−1
i Xi
)−1
. (3.5)
Finally, the prediction of the subject-specific effects, bi, are obtained by the namely best linear
unbiased predictors, BLUP’s:
bˆi = DˆZ
T
i Vˆ
−1
i (yi −Xiβˆ) (3.6)
where Dˆ and Vˆi are the REML estimators.
Dependence and correlation
The mean and variance of yij are represented by E(yij) = µij and Var(yij) = E{(yij−µij)2} = νij =
σ2j . Therefore, the dependence among the i−th subject responses at two different occasions, say
yij and yik, can be denoted by the covariance expression, Cov(yij , yik) = E{(yij−µij)(yik−µik)} =
νijk = σij . The ni × ni covariance matrix for the i−th subject is:
Vi = Var(yi) = Var

yi1
yi2
...
yini
 =

σ21 σ12 · · · σ1ni
σ21 σ
2
2 · · · σ2ni
...
...
. . .
...
σni1 σni2 · · · σ2ni
 (3.7)
Due to the fact that the magnitude of the covariance is somewhat difficult to interpret without
comparing it to the underlying variability of the variables, the correlation term between yij and yik,
ρjk is widely used: ρjk = E{(yij −µij)(yik−µik)}/(σjσk), being σj and σk the standard deviations
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of yij and yik, respectively. We can also define the ni × ni correlation matrix for the i−th subject:
Ri = Corr(yi) = Corr

yi1
yi2
...
yini
 =

1 ρ12 · · · ρ1ni
ρ21 1 · · · ρ2ni
...
...
. . .
...
ρni1 ρni2 · · · 1
 (3.8)
With longitudinal data, repeated observations on the same individual are not independent, and the
variance of repeated measurements is not usually constant. Consequently: 1) the heterogenity of
variance over time is accounted by allowing the elements on the main diagonal of the covariance
matrix to differ, and 2) dependence between responses leads that the off-diagonal elements of the
covariance matrix are usually non-zero, while these same elements are positive in the correlation
matrix.
Modeling covariance structure refers to representing Vi in expression (3.7) as a function of a rel-
atively small number of parameters. Functional specification of the covariance structure for the
linear mixed model is done through σ2In and D matrice. For simplicity, repeated measurements
are equally spaced assumed, so we may define the following basic structures: 1) Simple structure
specifies that the observations are independent, even on the same patient, 2) Compound symmetric
structure, which specifies that observations on the same patient have homogeneous covariance ho-
mogeneous variance, 3) Autoregressive (order 1) covariance structure, which specifies homogeneous
variance and also that covariances between observations on the subject patient are not equal, but
decrease toward zero with increasing lag, 4)Autoregressive plus random effects structure specifies
that covariance between observations on the same patient comes from two sources and 5) The
unstructured covariance specifies no patterns in the covariance matrix.
3.3 Survival Data Analysis
3.3.1 General features of survival data
The term survival analysis is generally defined as a set of methods for analyzing data where the
outcome variable is the time until the occurrence of a specific event of interest, usually designed
by E . This time is called survival time or event time.
Bearing the above into account, what makes survival data special is that the responses are times
and thus are not measured in the same way as other variables. In practice, this fact has two
important consequences: 1) the distribution of survival times is often highly left-skewed, and 2)
the only information we can have about some subjects is that they have not yet experienced the
event E at the last time point of follow-up, so these are termed censored or incomplete observations
(we do not know when these remaining subjects will experience the event). Considering these two
special features, standard statistical methods can not be applied to survival data.
Although there are various categories of censoring, the present work has only focused in
right-censoring mechanism, which occurs when the subject has not yet experienced the event
of interest at the time when the follow-up period ends. Consequently, all that is known about the
true survival time, t∗, is that it exceeds the observed survival time, t, at the end study. Furthermore,
over all this work it will be considered that the censoring is non-informative. In this regard,
it will be assumed the following three basic reasons why right-censoring might occur:
• The event of interest has not occurred by the end of the follow-up period (study end).
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• A subject is lost to follow-up during the study period due to not concerned causes to the event
of interest.
• A subject withdraws from the study (dropout) due to not concerned causes to the event of
interest.
Start of study End of study
Observation window
Origin
Subject 1
Administrative
closure
Origin
Subject 2 Dropout
Origin
Subject 3 Lost to follow-up
Origin
Subject 4 Event
Calendar time (years)
Figure 3.3. Illustration of different right-censored data cases.
3.3.2 Main survival functions
From now on, we assume that T is a non-negative continuous random variable which represents
the time until some specified event. Lets assume that its cumulative distribution function is F (t)
and its probability density function is f(t). In this situation, two functions are of central interest
in survival analysis:
• Survival function, S(t)
It denotes the probability of an individual surviving beyond time t, that is, the probability that
the event of interest has not yet occurred before time t. It is defined as
S(t) = Pr(T > t) = 1− F (t), for t ≥ 0. (3.9)
• Hazard function, h(t)
It represents the rate of occurrence of the event of interest at a given time t,
h(t) = lim
∆t→0
P(t < T < t+ ∆t|T ≥ t)
∆t
, with h(t) ≥ 0. (3.10)
Therefore:
h(t) =
f(t)
S(t)
= − d
dt
[log{S(t)}] (3.11)
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3.3.3 Non-parametric analysis of survival data
Kaplan-Meier estimator of the survival function
Let T be a positive random variable which represents the observed survival time, with survival
function S(t) , t ≥ 0. Given a random sample of i = 1, . . . , n individuals, the i−th subject provides
a potential true survival time, T ∗i , and a potential right-censored time, Ci, so that each individual
can be summarized by a couple of values, the observed survival time, Ti = min{T ∗i , Ci} and an
event indicator δi = I(T
∗
i ≤ Ci). In most cases, we can have ties between observed times, so two
or more individuals in the dataset share the observed survival time. Therefore, we only observe a
number of r (r < n) distinct survival times: in the same time there might be more than one event
observation, more than one right-censored observation or both type of survival data.
Let consider the order statistics of the r different observed survival times, T(1) < T(2) < . . . <
T(r) , for j = 1, . . . , r. Then, if tmax = T(r) is the largest observation time, the Kaplan-Meier
estimator (Kaplan and Meier, 1958) admits the following general form for all t < tmax:
SˆKM (t) =
 1 if t < T(1)∏
j:T(j)≤t
(
1− djnj
)
if t ≥ T(1)
(3.12)
where nj = card(R(T(j))) is the number of individuals who are at risk at a given observed time
T(j), and dj is the number of individuals who experience the event of interest at T(j). For values of
t beyond the largest observation time, tmax this estimator is not well defined.
Tests for two or more samples
Comparing two or more populations when when working with censored data can be performed by
simply comparing their respective estimated survival curves. Assuming two distinct groups, the
comparison is performed by the following non-parametric contrast:
H0 : S1(t) = S2(t) ∀ t such that 0 ≤ t ≤ τ
H1 : S1(t) 6= S2(t) for some t = tˆ such that 0 ≤ tˆ ≤ τ
(3.13)
where [0, τ ] is the window observation.
Let be t1 < t2 < ... < tD, with D ≤ n, the ordered time points with any event in the pooled sample.
In each time with any event, ti, we can observe di1 events and Ri1 subjects at risk in group 1, and
di2 events and Ri2 subjects at risk in group 2. Then, for the i−th time it is possible to construct
a 2× 2 contingency table:
Group Events Survivors Total at risk
1 di1 Ri1 − di1 Ri1
2 di2 Ri2 − di2 Ri2
Total di Ri − di Ri
Table 3.1. Explanatory table 2 × 2 with information on the number of events and the number of
individuals at risk, per group and in the overall sample, in the i−th global event time.
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By considering the differences between the observed event rates in each group, dij for j = 1, 2,
and the expected rates, di/Ri, tests can be constructed to weight the differences between the
two rates by suitably chosen weights, Wj(ti). The term usually applied to the weight function is
Wj(ti) = RijW (ti), so that the statistic test can be expressed as:
ZW (τ) =
∑D
i=1W (ti)
(
di1 −Ri1 diRi
)
√∑D
i=1W
2(ti)
Ri1
Ri
(
1− Ri1Ri
)(
Ri−di
Ri−1
) (3.14)
The evidence against the null hypothesis is summarized by the value ZW (τ), so that under H0 it
is verified that [ZW (τ)]
2 ∼ χ21 when the sample size is large enough. The weights used throughout
this work are those referred to the so-called Gρ family, proposed by Harrington and Fleming (1982):
WFH(ti) =
[
SˆKM (ti−1)
]ρ
(3.15)
where ρ is real value. When ρ = 0, the same weight is given to all differences between the two
estimated survival curves, corresponding to the so called log-rank test.
To conclude this section, it must be marked that we would follow the same reasoning as the exposed
in case of having more than two populations.
3.3.4 The proportional-hazards Cox model
Implementation of PH Cox model for censored survival data
The celebrated proportional-hazards Cox model (Cox, 1972) allows to model the conditional hazard
rate of survival times given certain baseline covariates. It relies on a fundamental assumption, the
proportionality of the hazards, implying that the factors investigated have a constant impact on the
risk over time. The model provides the conditional hazard function hi(t|wi) at time t of a subject’s
profile given by a set of p time-independent explanatory covariates (so-called baseline covariates),
wi = (wi1, wi2, . . . , wip)
T:
hi(t|wi) = h0(t)ψ(wi) , t ≥ 0 (3.16)
where:
h0(t): is an unspecified and non-negative baseline hazard function, representing the hazard function
when wi = 0.
ψ(wi): is a non-negative function which contains the information about the set explanatory time-
independent covariates that define the i−th subject’s profile.
This model is defined as a semiparametric because a parametric form is assumed only for the
covariate effect, ψ(wi). Among the possible parameterizations of the function ψ, the most used is
the one adopted an exponential expression: ψ(wi;γ) = exp(γ
Twi), where γ = (γ1, γ2, . . . , γp)
T is
the parameter vector:
hi(t|wi) = h0(t) exp{γ1wi1 + γ2wi2 + . . .+ γpwip} = h0(t) exp
{
p∑
k=1
γkwik
}
(3.17)
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The Cox model is often called a proportional hazards (PH) model because, if we look at two
individuals i and i′ with respective covariate values wi and wi′ , the ratio between their hazard
rates, HR, is constant, so their hazard rates are proportional to each other and do not depend on
time:
HR =
h(t|wi)
h(t|wi′) =
h0(t) exp
{∑p
k=1 γkwik
}
h0(t) exp
{∑p
k=1 γkwi′k
} = exp{ p∑
k=1
γk(wik − wi′k)
}
(3.18)
In the absence of any information for data distribution, the Cox model is a robust option for
different reasons: 1) The exponential part ensures that the estimated hazards are non-negative,
2) We can estimate the γk’s in the exponential part of the model, and 3) It is preferred over the
logistic model when survival time information is available and there is censoring.
Estimation of PH Cox model parameters
When the baseline hazard function is completely unspecified and the form of the function ψ(·) is
given, inference can be based on the namely partial likelihood function (Cox, 1975), which does not
require specification of h0(·). Assuming the presence of ties, information about parameters of the
model can be obtained from the relative orderings (i.e., ranks) of the survival times. Let consider the
d different ordered event times, t∗(1) < t
∗
(2) < . . . < t
∗
(d), and denote Rj = R(t(j)) = {i : Ti ≥ t(j)},
as the set of individuals who are “at risk” for experiencing the event at time t(j), j = 1, . . . , d and
R(Ti) as the risk set at the event time of the i−th subject, i = 1, . . . , n. Intuitively, the partial
likelihood function is a product over the set of observed event times of the conditional probabilities
of seeing the observed events, given the set of individuals at risk at those times:
Lp ∝
n∏
i=1
exp{γTwi}∑
j∈R(Ti) exp{γTwj}
⇒ logLp ∝
n∑
i=1
δi
γTwi − log
[ ∑
j∈R(Ti)
exp(γTwj)
] (3.19)
In particular, the maximum partial likelihood estimators are found by solving the partial log-
likelihood score equations:
∂ logLp
∂γT
=
n∑
i=1
δi
{
wi −
∑
j∈R(Ti) wj exp(γ
Twj)∑
j∈R(Ti) exp(γ
Twj)
}
= 0 (3.20)
It can be demonstrated that the maximum likelihood obtained from the maximization, γˆ, is
asymptotically normal an unbiased, efficient and asymptotically normal distributed, so if n →
∞ then γˆ ∼ N(γ, {E[I(γ)]}−1 ), where I(γ) is the Fisher matrix information.
In the presence of tied survival times, there are three widely used methods to treat ties between
event times in the Cox proportional hazards model: The Breslow approximation (Breslow, 1974),
the Efron approximation (Efron, 1977) and the exact method (Kalbfleisch and Prentice, 2002).
3.3.5 The extended Cox model with time-dependent covariates
So far, we have been considering the Cox PH model, where the i−th subject baseline covariates
wi, i = 1, . . . , n are measured at study entry (t = 0). However, since survival data occur over time,
important covariates that we wish to consider may also change within the observation period. We
refer to these as time-dependent covariates, yi(t).
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Types of time-dependent covariates
Let yi(t) denote the covariate vector at time t for the i−th subject, and let be Yi(t) = {yi(s), 0 ≤
s ≤ t} the associated covariate history up to time point t. It is very important to differentiate
between two different types of time-dependent covariates:
1. Exogenous covariates
The formal definition of exogenous covariates (Kalbfleisch and Prentice, 2002) requires such
covariates to satisfy the relation ∀s, t such that 0 ≤ s < t and ds→ 0:
Pr(s ≤ T ∗i < s+ ds|T ∗i ≥ s,Yi(s)) = Pr(s ≤ T ∗i < s+ ds|T ∗i ≥ s,Yi(t)) (3.21)
The above expression formalizes the idea that yi(.) is associated with the rate of events over
time, but its future path to any time t > s will not be affected by the occurrence of event at
time s. Thus, an external covariate is one whose path is completely predictable, i.e., its value
at any time t can be known infinitesimally before t (e.g., the time of the day).
2. Endogenous covariates
An endogenous time-dependent covariate is one where the change of the covariate over time is
related to the behavior of the individual, so it is measured with error and we can not predict
the future path of the covariate value. In this situation, the complete history is not available,
but measurements are only available at specific time-points.
Implementation of the extended Cox model
The local nature of the proportional hazards model reformulates itself easily to extensions that
allows for covariates that change over time. The basic idea lied in the fact of considering a counting
process model, where a subject contributes to the risk set for an event as long as an individual
is under observation at the time the event occurs and shares the same baseline hazards function
(Andersen and Gill, 1982; Therneau and Grambsch, 2000). In counting process notation, the event
process is written as {Ni(t), Ri(t)}, with Ni(t) denoting the number of events for subject i at time
point t and Ri(t) is at-risk indicator for the mentioned subject at time t. Let be:
wi = (wi1, wi2, . . . , wip)
T, vector of baseline covariates associated with the hazard of each subject
yi(t), covariate vector for subject i at time t
Yi(t) = {yi(s), 0 ≤ s ≤ t}, covariate history for subject i up to time t
Then, a namely counting process model with instantaneous rate of occurrence of the event of
interest can be formulated as
hi(t|Yi(t),wi) = h0(t)Ri(t) exp{γTwi + αyi(t)} (3.22)
where the regression coefficients γ and the parameter α has analogous interpretation as the coef-
ficients in the PH Cox model. In this case, the interpretation refers to a subject’s particular time
point, t. The estimation of γ and α is again based on the partial log-likelihood function:
Lp(γ) ∝
n∑
i=1
∫ ∞
0
(
Ri(t) exp{γTwi + αyi(t)} − log
[ ∑
j∈R(Ti)
Rj(t) exp{γTwi + αyi(t)}
])
dNi(t)
(3.23)
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Considerations on the extended Cox model
In the case of endogenous variables (the most common in clinical research) we do not know all the
covariate history. To try to solve this lack of information, time-dependent outcomes are assumed
to change value at follow-up time points, while remaining constant between these timings. In this
regard, Figure 3.4 shows the particular way the Cox model handles time-dependent covariates under
the counting process formulation:
Figure 3.4. Comparison on the treatment of baseline covariates in the PH Cox model (top panels) and
time-dependent covariates in the extended Cox model (bottom panels). Working with time-dependent
covariates, the PH assumption is only valid between consecutive time points.
However, it is not reasonable to assume that an endogenous covariate remains constant between
measurement points, specially when these points can be months or even years apart. In particular,
in the case of biomarkers this approach generally leads to biased estimations and standard errors
(Prentice, 1982).
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3.4 Joint Modeling framework
3.4.1 The classical Joint Modeling approach
The longitudinal submodel
To account for the fact that the longitudinal marker is an endogenous time-dependent covariate
measured with error (Kalbfleisch and Prentice, 2002) , it is assumed that the risk for an event
depends on the true and unobserved value of the endogenous variable at time t, denoted by mi(t).
Therefore, it must be estimated mi(t) in order to successfully reconstruct the complete longitu-
dinal history Mi(t). For this purpose, we utilize all the available measurements on each subject
{yi(tij), for i = 1, . . . , n and j = 1, . . . , ni} and postulate a suitable mixed effects model. We will
focus on normal data, describing the true subject-specific evolutions by a linear mixed effects model:

yi(t) = mi(t) + εi(t) = x
T
i (t)β + z
T
i (t)bi + εi(t)
bi ∼ N2(0,D)
εi(t) ∼ N (0, σ2)
(3.24)
The survival submodel
In order to quantify the effect of the true outcome mi(t) on the risk for an event at specific time t,
we use a relative risk model of the form (Therneau and Grambsch, 2000):
hi(t|Mi(t),wi) = h0(t) exp{γTwi + αmi(t)} , t > 0 (3.25)
where Mi(t) = {mi(s), 0 ≤ s ≤ t} denotes the history of the true unobserved longitudinal process
for subject i up to time point t. The parameter α quantifies the grade of association between the
true marker terms and the risk for an event.
In standard survival analysis, the baseline risk function h0(·) is typically left completely unspecified
(Cox, 1972; Andersen and Gill, 1982). However, within the joint modeling framework (Hsieh et al.,
2006) noted that leaving this function completely unspecified leads to an underestimation of the
standard errors of the parameter estimates, so it is necessary to explicitly define h0(·). Although
we could use the hazard function of a standard survival distribution (e.g. Weibull or Gamma), we
finally opted for a more flexible solution such a piecewise-constant model:
h0(t) =
Q∑
q=1
ξqI(νq−1 < t ≤ νq) (3.26)
where 0 = ν0 < ν1 < . . . < νQ denotes a split of the time scal, with νQ being the largest observed
time, and ξQ denotes the value of the hazard in the interval (νq−1, νq].
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The joint model formulation
On the basis of the expressed considerations, the true and unobserved outcome at a specific time
point t can be modeled by joining the two above approaches (Rizopoulos, 2012b):
{
yi(t) = mi(t) + εi(t) = x
T
i (t)β + z
T
i (t)bi + εi(t)
hi(t|Mi(t),wi) = h0(t)Ri(t) exp{γTwi + αmi(t)}
(3.27)
Particularly, the hazard at age t for the i−th individual, with a true longitudinal profile Mi(t) up
to time t, can be expressed as follows:
hi(t|Mi(t),wi) = h0(t)Ri(t) exp
[
γTwi + α{xTi (t)β + zTi (t)bi}
]
(3.28)
3.4.2 Estimation of parameters in joint modeling
The estimation method proposed for joint models in this work is maximum likelihood (Wulfsohn
and Tsiatis, 1997; Henderson et al., 2000; Hsieh et al., 2006), based on the maximization of the log-
likelihood corresponding to the joint distribution of the observed time-to-event and longitudinal
outcomes (Ti, δi,yi). To define this joint distribution we will assume that the vector of time-
independent random effects bi underlies both the longitudinal and survival processes. This means
that these random effects account for both the association between the longitudinal and event
outcomes, and the correlation between the repeated measurements in the longitudinal process
(conditional independence). Assuming non differential measurement error, we have:
p(Ti, δi,yi|bi;θ) = p(Ti, δi|bi;θ)p(yi|bi;θ) (3.29)
p(yi|bi;θ) =
∏
j
p{yi(tij)|bi;θ} (3.30)
where yi is the ni−vector of longitudinal responses of the i−th subject, p(·) an appropriate prob-
ability density function, and θ = (θTt ,θ
T
y ,θ
T
b )
T the full parameter vector, with θt denoting the
parameters for the event time outcome, θy the parameters for the longitudinal outcomes and θb
the unique parameters of the random-effects covariance matrix. In addition, we assume that given
the observed history, the censoring mechanism and the visiting process are independent of the true
event times and future longitudinal measurements. By visiting process we define the stochastic
mechanism that generates the time points at which longitudinal measurements are collected (Lip-
sitz et al., 2002), whereas for any time point t, we define as observed history all available information
for the longitudinal process prior to t.
The joint log-likelihood contribution for the i−th subject can be formulated as:
log p(Ti, δi,yi;θ) = log
∫
bi
p(Ti, δi,yi;θ)dbi =
= log
∫
bi
p(Ti, δi|bi;θt,β)
[∏
j
p{yi(tij)|bi;θy}
]
p(bi;θb)dbi
(3.31)
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where the conditional density for the survival part is written as:
p(Ti, δi|bi;θt,β) = {hi(Ti|Mi(Ti);θt,β)}δiSi(Ti|Mi(Ti);θt,β) =
=
[
h0(Ti) exp{γTwi + αmi(t)}
]δi exp(− ∫ Ti
0
h0(s){γTwi + αmi(s)}ds
)
(3.32)
In equation 3.31, p{yi(tij)|bi;θy} is the univariate normal density for the longitudinal responses,
and p(bi;θb) is the multivariate normal density for the random effects.
The maximization of the log-likelihood function, logL(θ) = ∑i log p(Ti, δi,yi;θ) can be achieved
using standard algorithms. In the joint modeling literature, the Expectation-Maximization algo-
rithm, EM (Dempster et al., 1977) has been traditionally used, which is a very general iterative
algorithm for incomplete-data problems. With this regard, (Rizopoulos et al., 2009) noted that the
score vector corresponding to logL(θ) is the key function required in the EM algorithm. The score
vector can be rewritten in the form:
S(θ) =
∂ logL(θ)
∂θT
=
∑
i
∫
bi
A(θ,bi)p(bi|Ti, δi,yi;θ)dbi (3.33)
where A(·) denotes the complete data score vector given by
A(θ,bi) = ∂{log p(Ti, δi|bi;θ) + log p(yi|bi;θ) + log p(bi;θ)}/∂θT
When the score equations corresponding to (3.33) are solved with respect to θ, with p(bi|Ti, δi,yi;θ)
fixed at the θ of the previous iteration, then this corresponds to an EM algorithm. In contrast, if
the score equations are solved with respect to θ considering p(bi|Ti, δi,yi;θ) also a function of θ,
then this corresponds to a direct maximization of the observed data log-likelihood, logLp(θ)
Standard errors for the parameter estimates can be based on the estimated observed information
matrix, i.e.,
Vˆar(θˆ) =
{
I(θˆ)
}−1
, I(θˆ) = −
n∑
i=1
∂Si(θ)
∂θ
∣∣∣∣∣
θ=θˆ
(3.34)
3.4.3 Residual analysis of joint models
The standard tools to assess model assumptions are residual plots, which can be used to deter-
mine the adequacy of the fitted joint model and can also indicate the presence of outliers. Some
of the most notable works for linear mixed models diagnostics are found in Santos Nobre and
da Motta Singer (2007), whereas reference papers focused on residuals for survival models were
presented by Harrell (2001) and Therneau and Grambsch (2000). However, getting residuals based
on the fitted joint model and the observed data is not straightforward, since they can be subject
to a informative not at random dropout mechanism. In order to avoid this difficulty, Rizopoulos
et al. (2010) suggested to impute longitudinal responses under the complete data model, thereby
working from a Bayesian perspective (Little and Rubin, 2002).
With regard to the longitudinal submodel, the fitted model is often checked by using subject-specific
(conditional) standardized residuals, r
(yss)
i (tij) = {yi(tij)− xTi (tij)βˆ − zTi (tij)bˆi}/σˆ, and marginal
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(population averaged) standardized residuals, r
(ysm)
i = Vˆ
−1/2
i (yi − Xiβˆ), where βˆ and σˆ denote
the maximum likelihood estimates under linear mixed model, bˆi are the empirical Bayes estimates
for the random effects, and Vˆi is the estimated marginal covariance matrix of yi.
For the survival submodel, the validation strategy is based on the martingale residuals, r
(tm)
i (tij),
and the Cox-Snell residuals, r
(tcs)
i . Martingale residuals focus on the counting process formulation,
and are obtained both at each subject’s time point, {tij , i = 1, . . . , n, j = 1, . . . , ni} where the
longitudinal outcome was measured, and at every observed survival time, Ti, i = 1, . . . , n. If
we denote by Ni(tij) the counting process for i-th subject at time tij , martingale residuals are
written as r
(tm)
i (tij) = Ni(tij)−
∫ tij
0 Ri(s)hˆ0(s) exp{γˆTwi + αˆmˆi(s)}ds, and Cox-Snell residuals as
r
(tcs)
i =
∫ Ti
0 hˆ0(s) exp{γˆTwi + αˆmˆi(s)}ds.
The problem in using the above defined residuals for inspecting the fit of joint models is that
their reference distribution is not directly evident. Complications arise due to the non random
dropout in the longitudinal process caused by the occurrence of events. That is, the observed data,
upon which the residuals are calculated, are not a random sample of the target population. To
clarify this, we define for each subject the observed and missing part of the longitudinal response
vector. The observed part yoi = {yi(tij) : tij < Ti, j = 1, . . . , ni} contains all observed longitudinal
measurements of the i−th subject before the observed event time, whereas the missing part ymi =
{yi(tij) : tij ≥ Ti, j = 1, . . . , n′i} contains the longitudinal measurements that would have been
taken until the end of the study, had the event not occurred. Under these definitions, it can be
derived the dropout mechanism, which is the conditional distribution of the time-to-dropout given
the complete vector of longitudinal responses (yoi ,y
m
i ),
p(T ∗i | yoi ,ymi ;θ) =
∫
bi
p(T ∗i |bi;θ)p(bi | yoi ,ymi ;θ)dbi (3.35)
which still depends on ymi through the posterior distribution p(bi|yoi ,ymi ;θ). It is this feature of
joint models that complicates inspection of residual plots, because a potential systematic behavior
is not necessarily indicative of a model misfit. Thus, conclusions from common residual plots in
the joint model framework should be drawn with extreme caution.
3.4.4 Predicted survival in joint models
Once the model has been validated, a powerful feature is to derive satisfactory results in terms of
survival predictions. Thus, considering the sample Dn = {Ti, δi, yi; i = 1, . . . , n} on which the joint
model was fitted, the goal consists of predicting conditional probability of surviving time for a new
subject i that provides a set of longitudinal measurements, Yi(t) = {yi(s); 0 ≤ s < t} and a vector
of baseline covariates, wi. Flexibility provided by joint modeling approach is in line with a growing
trend towards personalized medicine (Garre et al., 2008; Proust-Lima and Taylor, 2009; Rizopoulos,
2011). In particular, the real challenge focuses of being able to estimate these probabilities not
only at each one of the time points measurements, but also at a generic time u > t given survival
up to t
pii(u|t) = Pr(T ∗i ≥ u | T ∗i > t,Yi(t),wi,Dn;θ∗) (3.36)
where θ∗ denotes the true parameter values.
This approach therefore allows to obtain the so called survival dynamic predictions for the i−th
subject, arising from its survival curve updating on the basis of any new longitudinal information
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subsequently collected. Hence, as new information at time t′ > t joins existing longitudinal mea-
surements, one can update the estimated survival curve pii(u | t) to pii(u | t′), and therefore proceed
in a time dynamic manner.
The estimation of the subject-specific conditional survival probabilities takes full advantage of the
conditional independence used to define the joint model. Using a Bayesian formulation (Proust-
Lima and Taylor, 2009; Rizopoulos, 2011), the problem can be written as:
Pr(T ∗i ≥ u | T ∗i > t,Yi(t),Dn) =
∫
θ
Pr(T ∗i ≥ u | T ∗i > t,Yi(t);θ)p(θ | Dn)dθ (3.37)
The first part of the above integrand is given by
Pr(T ∗i ≥ u | T ∗i > t,Yi(t);θ) =
∫
bi
Si{u | Mi(u,bi,θ);θ}
Si{t | Mi(t,bi,θ);θ} p(bi | T
∗
i > t,Yi(t);θ)dbi (3.38)
where Si(·) denotes the survival function, and furthermore it has been explicitly noted that the
true longitudinal history Mi(·) is a function of both the random effects and the parameters. For
the second part of equation (3.37), it is assumed that the sample size n is sufficiently large, such
that {θ,Dn} can be well approximated by N{θˆ, V̂ar(θˆ)}.
By combining 3.37, 3.38 and {θ,Dn} ∼ N{θˆ, V̂ar(θˆ)}, it can be derived a Monte Carlo estimate of
pii(u | t) using the following simulation scheme:
1) Draw θ(l) ∼ N{θˆ, V̂ar(θˆ)}
2) Draw b
(l)
i
3) Compute pi
(l)
i (u | t) = Si{u | Mi(u,b(l)i ,θ(l));θ(l)}/Si{t | Mi(t,b(l)i ,θ(l));θ(l)}
The three steeps are repeated l = 1, . . . , L times, where L denotes the number of Monte Carlo
samples. The realizations {pi(l)i (u | t) , l = 1, . . . , L} can be used to derive point estimates of
pii(u | t), such as the median and the mean values:
pii
(l)(u | t) = median{pi(l)i (u | t) , l = 1, . . . , L} (3.39)
pii
(l)(u | t) = L−1
L∑
l=1
pi
(l)
i (u | t) (3.40)
From the estimates, it is also possible to compute the standard errors using the sample standard
deviation over the Monte Carlo samples and the confidence intervals through the sample percentiles.

CHAPTER 4
A JOINT MODEL FOR THE PCA DATASET
4.1 Longitudinal analysis of PSA level over time
4.1.1 Specific random effects model
The general linear mixed model expression (Chapter 3, Section 3.2.3) can be specified as a particular
mixed effects model, where each of the n = 2415 subjects from the PCa Dataset is modeled using
subject-specific intercept and slope terms (q = 2). In our study, the observed longitudinal outcome
corresponds to the LLPSA values for individual i at time t.
Since subjects are randomly sampled from a population, it is reasonable to assume that the subject-
specific regression coefficients, β˜i0 and β˜i1, are also randomly sampled from the corresponding
population of regression coefficients, with (β˜i0, β˜i1)
T ∼ N2((β0, β1)T,D), and the error terms are
also assumed to be normally distributed, εij ∼ N (0, σ2). Therefore, the LLPSA subject profile is
modeled as
LLPSAi(t) = β˜i0 + β˜i1t+ εi(t) . (4.1)
Each subject-specific coefficient can be separated into a fixed and random part, β˜i0 = β0 + bi0,
β˜i1 = β1 + bi1, so our random effects model is finally expressed as:

LLPSAi(t) = β0 + bi0 + (β1 + bi1)t+ εi(t)
bi ∼ N2(0,D)
εi(t) ∼ N (0, σ2)
(4.2)
where LLPSAi(t) is the outcome value for the i−th subject, i = 1, . . . , 2415, at time t, β = (β0, β1)T
is the fixed effects vector for the intercept and slope terms, bi = (bi0, bi1)
T is the random effects
vector for the intercept and slope, D = (dlk)l,k=1,2 is the 2 × 2 variance-covariance matrix, where
d11 = Var(bi0) = σ
2
b0
, d22 = Var(bi1) = σ
2
b1
, and d12 = Cov(bi0, bi1) = ρb0b1σb0σb1 , and εi(t) is the
sample error term on the i−th subject at time t.
We used an unstructured covariance matrix in the longitudinal analysis, that is, there are no
constraints and each variance and each covariance is estimated uniquely from the data. This last
assumption results in that variance and covariance values are very close to what the data reflect,
and does not require knowledge or justification of a more restrictive pattern.
4.1.2 Analyzing response profiles
In order to determine any trends in the LLPSA mean response over time, a simple time plot can be
obtained by connecting successive repeated measurements on the same subject with straight lines.
However, it must be kept in mind that we do not know the subject’s profile evolution between
successive visits, as we only have information at specific time points.
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Figure 4.1 shows the time-plots of LLPSA, where the consecutive observations on each man are
connected through line segments. This plot offers a very good idea of the specific trajectories for
all subjects, and it is colloquially known as spaghetti plot or profile plot. Interesting features on
the referred plot are the wide variation in the initial values of LLPSA and the heterogeneity in
the subsequent trajectories for different men. Also, it can be appreciated a marginal positive trend
with a gentle slope, as well as a potential mildly nonlinear component.
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Spaghetti plot for the PCa Dataset
Figure 4.1. LLPSA subjects profiles across time (age in years) for the participants in the Spanish
section of ERSPC.
However, in practice it is very difficult to track the response profile of any particular individual
when the spaghetti plot contains so many individuals as in the above figure. As a result, it is more
useful to present a time plot with joined line segments for only a relatively small and representative
random sample selected from the study participants.
Figure 4.2 shows the LLPSA profile plots according to presence or absence of prostate cancer
diagnosis. The top panel of the figure shows the LLPSA trajectories for the 116 men diagnosed
with prostate cancer, while the bottom panel shows a random sample of 116 men chosen among the
2299 not diagnosed men. The first relevant aspect is that both panels indicated a similar behaviour
in the general trend and in the variability of the LLPSA values. However, the prostate cancer
group had higher mean values of LLPSA, in comparison with the non prostate cancer group. This
information gives a clear support to the relevance of PSA measurements to explain the time to
prostate cancer diagnosis.
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Figure 4.2. LLPSA subjects profiles across time (age in years) for the 116 men who developed prostate
cancer during the follow-up period (top panel) and for 116 randomly selected men without a prostate
cancer diagnosis (bottom panel), for the participants in the Spanish section of ERSPC.
4.1.3 Random effects model results for the PCa Dataset
Due to the high of variability of the subjects’s responses at study entry, we first assumed random
intercepts in the model,
LLPSAi(t) = β0 + bi0 + β1t+ εi(t), (4.3)
and then allow random intercepts and slopes,
LLPSAi(t) = β0 + bi0 + (β1 + bi1)t+ εi(t) . (4.4)
In both cases, restricted maximum likelihood estimates are presented in Table 4.1.
The linear mixed model with random intercept assumes that each individual has a particular
bi0, and assumes a common slope. In this model there are two estimated variance components:
σˆ =
√
V̂ar(εi(t)) = 0.107 and σˆb0 =
√
V̂ar(bi0) = 0.223. The total variation (marginal variance)
between any pair of LLPSA responses within the i−th subject is given by the sum of between-
subject variability, σˆ2b0 , and within-subject variability, σˆ
2: V̂ar{LLPSAi(t)} = σˆ2b0 + σˆ2 = 0.2232 +
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0.1072 = 0.2472 = 0.061, whereas the estimate marginal covariance between any pair of responses
is Ĉov{LLPSAi(tj),LLPSAi(tk)} = σˆ2b0 = 0.2232 = 0.050.
As an example, we extract the estimated covariance matrix for subject i = 556 in the PCa Dataset,
who has n556 = 4 visits at time points {t556,1 = 62.74, t556,2 = 66.93, t556,3 = 68.27, t556,4 = 69.58}
years,
Model Estimate Std. Error 95% Conf. Int. p-value
Random intercept
β0 0.368 0.009 (0.349, 0.386) < 0.0001
β1 0.014 0.001 (0.013, 0.015) < 0.0001
σ 0.107 – (0.104, 0.110) –
σb0 0.223 – (0.216, 0.231) –
AIC -2312.078 – – –
Random intercept and slope
β0 0.364 0.008 (0.347, 0.380) < 0.0001
β1 0.014 0.001 (0.013, 0.016) < 0.0001
σ 0.105 – (0.101, 0.108) –
σb0 0.147 – (0.130, 0.166) –
σb1 0.006 – (0.004, 0.008) –
ρb0b1 0.855 – (-0.738, 0.998) –
AIC -2416.572 – – –
Table 4.1. Estimated parameters for the linear mixed effects models fit to the PCa Dataset by REML.
Vˆ556, intercept =

0.061 0.050 0.050 0.050
0.050 0.061 0.050 0.050
0.050 0.050 0.061 0.050
0.050 0.050 0.050 0.061

Therefore, in the random intercept model, for subject i = 556 the percentage of total variation that
is attributed to within-subject variability is (0.1072/0.2472) · 100 = 18.6%, with (0.2232/0.2472) ·
100 = 81.4% of total variation attributable to between-subjects variation in their general level of
LLPSA (e.g., attributable to random intercepts).
The estimated correlation between any pair of measurements on the same subject is obtained by the
named intra-class correlation Ĉorr{LLPSAi(tj),LLPSAi(tk)} = σˆ2b0/(σˆ2b0 + σˆ2), so the estimated
correlation matrix for subject i = 556 is:
Rˆ556, intercept =

1 0.814 0.814 0.814
0.814 1 0.814 0.814
0.814 0.814 1 0.814
0.814 0.814 0.814 1

Additional flexibility is introduced in the random intercept and slope model, so that now the
marginal variance of the i−th response is not constant but depends on the time point t, V̂ar{LLPSAi(t)} =
σˆ2b0 + 2Ĉov(bi0, bi1)t + σˆ
2
b1
t2 + σˆ2, and also the marginal covariance between any pair of responses
within the i−th subject, Ĉov{LLPSAi(tj),LLPSAi(tk)} = σˆ2b0 + 2Ĉov(bi0, bi1)(tij + tik) + σˆ2b0tijtik.
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Again, the covariance matrix is obtained for the individual i = 556,
Vˆ556, intercept-slope =

0.069 0.064 0.065 0.067
0.064 0.081 0.072 0.074
0.065 0.072 0.085 0.076
0.067 0.074 0.076 0.089
 .
The total variation between any pair of LLPSA responses within the i−th subject is now σˆ2b0 +
σˆ2b1 + σˆ
2 = 0.1472 + 0.0062 + 0.1052 = 0.1812 = 0.033, and the between-subject variation accounts
for {(σˆ2b0 + σˆ2b1)/(σˆ2b0 + σˆ2b1 + σˆ2)} · 100 = 66, 4% of all variability. From this result, a 99.8% is
explained by the random intercept. It must be noted how the value of Vˆar(bi0) decreased in this
model in comparison to the random intercept model, as now the model also relies on the random
slope effect to explain between-subject variability.
The corresponding correlation matrix is derived from
Ĉorr{LLPSAi(tj),LLPSAi(tk)} =
σˆ2b0 + 2Ĉov(bi0, bi1)(tij + tik) + σˆ
2
b0
tijtik√
σˆ2b0 + 2Ĉov(bi0, bi1)t+ σˆ
2
b1
t2j + σˆ
2
√
σˆ2b0 + 2Ĉov(bi0, bi1)t+ σˆ
2
b1
t2k + σˆ
2
Rˆ556, intercept-slope =

1 0.852 0.855 0.858
0.852 1 0.868 0.870
0.855 0.868 1 0.874
0.858 0.870 0.874 1

As expected, the general trend is that variances increase over time, whereas correlation decrease.
It is evident that the random intercept and slope model offers greater flexibility in modeling the
marginal covariance matrix, although it imposes a particular relationship that not necessarily is
correct. Furthermore, it also draws attention the high correlation between the random effects,
one may think that the random intercept effect is sufficient to explain the subject specific trend.
However, R2b0b1 = 0.731 < 0.80, and therefore the correlation degree is not yet extremely high.
This model flexibility is also translated into an improvement that can be measured by the Akaike’s
Information Criterion, AIC. In this regard, a formal comparison is possible since the random
intercept and slope model is nested into the random intercept model. The maximized AIC value
was -2312.078 in random intercept model, while it decreases to -2416.572 when also allowing random
slope. This decrease in AIC is quite substantial and statistically significant (ANOVA test) with
p-value < 0.0001. So, in what follows in this section the longitudinal analysis is implemented with
random intercept and slope model.
4.1.4 Subject specific predictions
A typical objective of longitudinal analysis is to characterize individual behavior. As mentioned
above, the linear mixed effects model (which contains the random coefficient model as a special case)
is a subject-specific model in the sense that an individual’s “regression model” can be characterized
at time t as having “mean” xTi (t)β+z
T
i (t)bi. Thus, to characterize the i−th specific subject profile
with the random intercept and slope model, it is necessary to predict bi = (bi0, bi1)
T for this subject
in the model
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
LLPSAi(t) = 0.364 + bi0 + (0.014 + bi1)t+ εi(t)
bi ∼ N2(0, Dˆ)
εi(t) ∼ N (0, σˆ2)
where Dˆ =
[
0.1472 0.001
0.001 0.0062
]
and σˆ2 = 0.1052.
As already commented, the prediction of the random effects is carried out using the BLUP predictor.
To illustrate how the fitted mixed model works, five subjects with three visits (i.e., with sufficient
longitudinal information) were randomly selected from our source dataset, i = 100, 116, 128, 291, 543.
For each of them, a subject-specific profile was fitted by the predicted random effects, and the re-
sults were printed along with the global average response. The results are displayed in Figure 4.3
and show that the random effects model seems to fit adequately these individuals..
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a) Measurements of randomly selected subjects
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b) Connection of subject measurements
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Figure 4.3. Representation of five subject specific profiles from the random intercept and slope model:
a) LLPSA responses over time of the five selected subjects, b) Correlation between longitudinal re-
sponses, c) Average response across the individuals in the population, and d) Predicted subject-specific
profiles.
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A critical issue of the PCa Dataset is the existence of 573 subjects (23.7% of the total) with
only one LLPSA measurement. For these special cases there is evidence that the model captures
the information provided by subjects with more than one visit, assigning particular linear profiles
whose slopes have a variability range with Vˆar(b1) = σ
2
b1 = 0.006
2. Figure 4.4 presents the predicted
profiles for those 573 subjects without longitudinal follow-up are presented.
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Figure 4.4. Prediction of subject-specific trens for the 573 individuals with only one LLPSA measure-
ment.
Figure 4.4 shows that the slope allocation is not at random: the higher the LLPSA value, the greater
the profile slope. The estimation is obtained using the information collected from the profiles with
large number of visits.
4.2 Survival analysis of time to prostate cancer diagnosis
4.2.1 Survival results from non-parametric analysis
The Kaplan-Meier estimate is the simplest way of estimating survival over time. The Kaplan-Meier
survival curve is defined as the probability of surviving a given period of time while considering
time in many small intervals. There are three assumptions used in this analysis: 1) It is assumed
that at any time subjects who are right-censored have the same survival prospects as those who
continue to be followed, 2) The survival probabilities are the same for subjects recruited early and
late in the study and 3) The event happens at the registered time.
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Panel a) in Figure 4.5 shows the Kaplan-Meier (KM) estimate of the survival function of time to
diagnosis for the study sample. The probability of prostate cancer diagnosis free survival decreases
at a continuous rate of change in men aged 55 to 75 years and, due to censoring, it stabilizes at the
estimated survival value 0.914. As previously mentioned, a PSA ≥ 3 ng/ml is a key threshold in the
screening program. Panel b) from the same plot displays the KM estimate of the survival function
of time to PCa diagnosis for individuals whose first PSA measurement is below or above that limit.
A rapid decrease of the survival function for individuals with the first PSA ≥ 3 ng/ml is observed
and a significant difference exists between the two categories (log-rank test with p-value < 0.0001).
The estimated probability of prostate cancer diagnosis free survival for 75 years old subjects if their
baseline PSA is below or above 3 ng/ml is 0.946 or 0.704, respectively.
a) KM survival curve for time−to−event data
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Figure 4.5. Plot of the Kaplan-Meier estimate of the survival function of time to prostate cancer
diagnosis in the Spanish ERSPC study a) overall subjects in the sample, and b) stratified (and 95%
confidence intervals) by the value (below or above 3 ng/ml) of the first PSA measurement.
Since time from study entry to prostate cancer diagnosis can vary depending on the AGE, it
is important to account for this issue. Figure 4.6a displays KM survival curves of time from
study entry to prostate cancer diagnosis, stratified by tertiles of age at entry ([45, 55), [55, 60)
and ≥60 years). An overall significant difference between the three categories is observed (log-
rank p-value < 0.0001). Specifically, younger participants show better PCa diagnosis free survival
estimates. However, since age and PSA levels are positively correlated, a joint analysis is needed.
From this perspective, Figure 4.6b illustrates a significant difference between groups by AGE×PSA
level at study entry (log-rank p-value < 0.0001), as well as a trend across the categories. Therefore,
it will be necessary to consider the role of the interaction between AGE and PSA measurement at
the first visit in the survival approach as a covariate to explain the time to event diagnosis.
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a) KM survival curves based on time since first visit 
 and stratified by AGE (years) at first visit
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 stratified by AGE (years) and PSA (ng/ml) at first visit
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Figure 4.6. Plot of the Kaplan-Meier estimate of the survival function of time since the entry time to
prostate cancer diagnosis in the Spanish ERSPC study a) stratified by age at entry, and (b) stratified
by age and PSA level at entry.
4.2.2 Survival results for the Cox model
PH Cox model approach
As we have noted in the precedent subsection, there is an important point to explain the prostate
cancer diagnosis in the degree of association between the LLPSA level at first visit and the cor-
responding AGE, hereinafter called LLPSA0 and AGE0, respectively. These covariates have been
treated as “baseline values”. Taking this into account, for the i−th subject the following Cox PH
model was fitted
hi(t|wi) = h0(t)Ri(t) exp{γAGE0i × LLPSA0i} , (4.5)
and the results displayed in Table 4.2 were obtained,
γˆ SE(γˆ) HR 95% CI p-value
0.119 0.012 1.126 (1.099, 1.153) < 0.0001
Table 4.2. Estimated parameter of Cox PH model, γˆ with AGE0i × LLPSA0i as baseline covariate
from PCa Dataset.
The fitted Cox PH model is
hi(t|wi) = h0(t)Ri(t) exp{γAGE0i × LLPSA0i} = h0(t)Ri(t) exp{0.119AGE0i × LLPSA0i}. (4.6)
The fact that the baseline covariate AGE0×LLPSA0 is significant and positive (γˆ = 0.119, p-value <
0.0001) implies that the i−th subject LLPSA0i level is significantly related with his corresponding
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age, AGE0i, and the risk increases with the AGE0 × LLPSA0 values. Consequently, the hazard
associated to a one-unit change of LLPSA0i not only depends of the recorded variation, but also of
the baseline age at which the referred change takes place. As an illustration of the risk evolution,
we can compare the hazard risk between two subjects that have the same LLPSA0 level variation
but at different baseline ages.
Let be one subject i who is 50 years (AGE0i = 5) and increases his PSA0i from 5 to 10 ng/ml (i.e.,
LLPSA0 from 1.03 to 1.22),
ĤRi =
h0(t)Ri(t) exp{0.119 · 5 · 1.22}
h0(t)Ri(t) exp{0.119 · 5 · 1.03} = exp{0.119 · 5 · (1.22− 1.03)} = 1.12,
and other subject i’ who experiences the same increase but at 65 years old (AGE0i′ = 15):
ĤRi′ =
h0(t)Ri′(t) exp{0.119 · 15 · 1.22}
h0(t)Ri′(t) exp{0.119 · 15 · 1.03} = exp{0.119 · 15 · (1.22− 1.03)} = 1.40.
In this approach, if both subjects increase their corresponding prostate cancer diagnosis risk (as
already known since γˆ > 0), the older has a risk increase a {(1.40− 1.12)/1.12} · 100 = 25% higher
than the younger one.
Extended Cox model approach
In practice, we can distinguish between the two types variables using the concept of predictability:
an external or predictable variable is one whose value at any time t is known infinitesimally before
t, whereas a endogenous or internal is not predictable. Standard time-to-event regression models
(e.g., PH Cox model) treats time-dependent covariates like external, but this assumption is not
true in the case of variables under biological processes as in the case of clinical biomarkers (e.g.,
PSA). The extended Cox Model works with the observed covariant history Y, from which we only
know the observed response at some specific points, and additionally these measures are associated
to an measurement error. Thus, if we treat internal covariates as external, we may obtain biased
results.
When handling with endogenous covariates, the extended Cox Model must be understood as an
intermediate step towards a model that takes into account, at specific time t, the fully specification
of the true variable path up to t, denoted by M(t) (Chapter 3, Subsection 3.4.1).
4.3 Joint modeling results
4.3.1 Estimation of joint model
We proceed by specifying and fitting the joint model that explicitly accounts for the endogeneity
of the LLPSA marker. In particular, it has been taken into consideration two possible joint models
depending on the longitudinal submodel adopted:
M1: A linear mixed model with random intercept for the longitudinal submodel and a relative risk
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model including the baseline interaction between AGE and LLPSA, that is{
yi(t) = mi(t) + εi(t) = β0 + bi0 + β1t
hi(t|Mi(t),wi) = h0(t)Ri(t) exp{γAGE01 × LLPSA0i + αmi(t)}
(4.7)
where bi0 ∼ N (0, σ2b0) and εi(t) ∼ N (0, σ2).
M2: A linear mixed model with random intercept and slope for the longitudinal submodel and a
relative risk model including the baseline interaction between AGE and LLPSA,{
yi(t) = mi(t) + εi(t) = β0 + bi0 + (β1 + bi1)t
hi(t|Mi(t),wi) = h0(t)Ri(t) exp{γAGE01 × LLPSA0i + αmi(t)}
(4.8)
where bi ∼ N2(0,D), being D a unstructured 2 × 2 matrix for random effects, and εi(t) ∼
N (0, σ2).
The joint model with longitudinal submodel M1 and longitudinal submodel M2 (right columns)
parameter estimates are shown in Table 4.3 with their 95% respective confidence intervals. Inference
focuses on the probability of the data (random) given the hypothesis (fixed) and the asymptotic
properties of a specific estimator, under repeated sampling. As a result, confidence intervals for
parameters can be derived.
M1: Random intercept M2: Random intercept and slope
Parameters Estimate 95% CI Estimate 95% CI
Longitudinal submodel
β0 0.363 (0.345, 0.382) 0.362 (0.355, 0.369)
β1 0.014 (0.013, 0.015) 0.014 (0.014, 0.015)
σ 0.107 – 0.082 –
σb0 0.224 – 0.138 –
σb1 – – 0.005 –
ρb0b1 – – 0.999 –
Survival submodel
γ -0.048 (-0.086, -0.009) -0.002 (-0.033, 0.030)
Association
α 7.139 (6.001, 8.272) 5.490 (4.767, 6.213)
Goodness of fit
AIC -977.109 – -8453.005 –
Table 4.3. Joint model estimates for ML analyses of longitudinal LLPSA values and prostate cancer
diagnosis. Two options have been considered for the longitudinal submodel: mixed model with random
intercept and mixed model with random intercept and slope. The survival submodel follows a piecewise-
constant model, and considers the AGE0 × LLPSA0 interaction.
The parameter estimates for joint model (4.7) under the general unstructured random effects co-
variance matrix, showed a high correlation between the random effects, ρb0b1 = 0.999. To avoid
unstability and colinearity in the estimates, we discarded the model that assumed non-independent
random effects. Moreover, the joint model that assumed independent random effects did not pro-
vide a statistically significant AGE0 × LLPSA0 interaction. Then, we decided to include only
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the random intercept effect in the longitudinal approach and select the joint model
with M1 as longitudinal submodel, with a relative risk model:
hi(t|Mi(t),wi) = h0(t)Ri(t) exp{γAGE01 × LLPSA0i + αmi(t)} =
= h0(t)Ri(t) exp{γAGE0i × LLPSA0i + α(β0 + bi0 + β1t)},
(4.9)
where bi0 ∼ N (0, σ2b0), and εi(t) ∼ N (0, σ2).
With respect to the selected joint model (4.7), in contrast to the survival submodel result the sign
for the baseline survival covariate is negative, γˆ = −0.048, p − value = 0.015, so after combining
longitudinal and survival processes, the prostate cancer risk decreases with the AGE0 × LLPSA0
covariate. There is an increasing trend of prostate cancer risk as AGE0 × LLPSA0 at study entry
increases, which results from moderate or high values of the true profiles m(t) slightly counterbal-
anced by the protective effect of the interaction.
Another important point from the results consists of noting both the positive value and the high
significance of the association parameter, αˆ = 7.139, p− value < 0.0001, so the PSA (expressed by
LLPSA) level has a strong positive association with the risk for prostate cancer.
Table 4.4 presents the estimated HRs that correspond to different increases in PSA for a sample
of PSA values. For instance, a unit increase in the PSA values represents a 4.7, 1.9 or 1.2-fold
increase in the hazard rate of prostate cancer, for PSA values 1, 3 or 10, respectively. Therefore,
the same changes in PSA have more impact on prostate cancer risk for low PSA values. However,
for particular percentual increases of PSA, the HRs did not vary much across different PSA values.
Increases of 10% or 20% in PSA levels result in HRs around 1.2 or 1.4, respectively.
PSA level (ng/ml)
1 2 3 5 10 15 20
HR for an 1 unit 4.63 2.50 1.89 1.47 1.20 1.12 1.09
increase of 10% 1.22 1.24 1.24 1.22 1.20 1.18 1.17
PSA of 20% 1.48 1.51 1.50 1.47 1.41 1.37 1.35
Table 4.4. Estimated hazard ratio (HR) of prostate cancer for different increases of PSA at specific
PSA values, under the joint model.
It is also important to point out that the joint model allows to assess the impact, by means of the
hazard ratio exp[αˆ{log(1 + PSA + ∆PSA))− log(1 + log(1 + PSA))}] for a ∆PSA variation in PSA
values depending on the PSA reference level. Figure 4.7 illustrates a contour plot of the estimated
HR for a ∆PSA variation as a function of PSA. For instance, we can see that an increase of 2.0
ng/ml in PSA would represent a higher impact for a subject with 1.0 ng/ml of PSA (ĤR = 10)
than for a subject whose PSA value was 8.0 ng/ml (ĤR = 1.5).
Next sections of this chapter focus on the joint model formulation for the PCa Dataset: A longitu-
dinal submodel with random intercept and a survival submodel considering the interaction between
AGE and LLPSA at study entry. From this model, the residuals validation and survival prediction
results are obtained.
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Figure 4.7. Contour plot of the estimated HR for a ∆PSA variation as a function of PSA.
4.3.2 Validation of the joint model
When it comes to using the joint model fitted for the PCa Dataset, a prerequisite step is to validate
the model’s assumptions. The standard and most frequently used tools to assess these assumptions
are based on residual plots.
Diagnostic plots for the fitted joint model are shown in Figure 4.8. The two top charts provide the
residual plots to validate the longitudinal submodel, whereas the bottom plots are used to assess
the adequacy of the survival submodel.
Concerning to the standard linear mixed-effects model (i.e., the longitudinal part), the subject-
specific residuals plot (top left panel) predicts the conditional errors at the specified time points,
εi(tij), which seem to fulfill the homoscedasticity and normality assumptions. In addition, the fitted
loess curve in the standardized marginal residuals plot (top right panel) displays no systematic
pattern, with a random scatter around a constant zero mean, which confirms the suitability of the
structure for the fixed effects design (ni × p)-dimensional matrix for a given subject, Xi.
The survival marginal residuals (bottom left panel) show a slight deviation of the loess smother
from zero and confirm the appropriateness of the chosen functional form for the PSA values. The
bottom right panel, that shows the comparison between the KM curve for the Cox-Snell residuals
and the unit exponential distribution, detects only some lack of fit for residual values on the right
tail of the distribution.
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Standardized marginal residuals vs fitted values
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Figure 4.8. Diagnostic plots for the longitudinal submodel (two top panels) and the survival submodel
(two bottom panels) for the fitted joint model.
4.3.3 Dynamic predictions of survival probabilities
In this section we focus on expected survival for all the 2415 subjects from the PCa Dataset, but
within the joint modelling framework. In particular, based on the joint model fitted, it would be
possible to predict survival probabilities for a new subject that has provided a set of longitudinal
measurements.
As already explained, the fitted joint model allows to obtain individual dynamic predictions of
prostate cancer free survival probabilities based on the observed longitudinal profile at specific time
points. As an example to illustrate how changes in the LLPSA profiles are reflected in changes in
the dynamic updates of the survival probabilities, Figure 4.9 shows how the estimated survival curve
for the subject i = 556 from PCa Dataset is updated as the number of PSA measurements grows
from one to four at the corresponding visits: {t556,1 = 62.74, t556,2 = 66.93, t556,3 = 68.27, t556,4 =
69.58} years. The idea behind this four-panel graph consists of including at each time point the
last available LLPSA measurement and the estimated survival curve after this point.
In our case, the median estimator was employed to represent survival probabilities. From the
four plots included in the figure, there is a constant increase in the true level of LLPSA, leading
to a lower prostate cancer free survival probability, which highlights the relevance of an accurate
follow-up when aiming implement an individualized screening approach.
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Figure 4.9. Successive LLPSA longitudinal trajectories and dynamic prostate cancer free survival
probabilities (median estimator and 95% pointwise confidence intervals for pii(u|t) at each time point),
for subject i = 556 from the PCa Dataset.
Therefore, it is possble to obtain the survival probabilities for subject i = 556, of whom we know
that he was free diagnosed until the end of the study (when he was 81.80 years old), although his
last PSA measurement took place at age of 69.58 (4.10).
Conditional survival probabilities for subject i=556
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Figure 4.10. Survival probabilities for subject i = 556 from the PCa dataset. The solid and dashed
lines correspond to the median and mean estimators, respectively.

CHAPTER 5
DISCUSSION AND FUTURE RESEARCH
5.1 Discussion and Conclusions
In recent years, clinical researchers have shown a great interest to record the values of key longitu-
dinal covariates until the occurrence of a particular event in a subject. However, such covariates are
usually associated to inherent biological processess of each subject, so that a separate analyses of
longitudinal and survival data may lead to inefficient or biased results. In order to overcome these
protential difficulties, it is necessary to advance towars a jointly modelization of both approaches.
In this line, our study main goal has been to understand and apply the necessary statistical concepts
to model adequatly endogenous time-dependent covariates. In this regard, we have illustrated the
capabilities of the joint modelling for longitudinal and time-to-event data using shared parameter
models. These models are applicable either to account for the effect of a time-dependent covariate
measured with error in a survival analysis context or to correct for non at random dropout in the
analysis of longitudinal outcomes. To choose methods for inference, the joint likelihood method
generally produces most reliable results if the assumed models and distributions are correct. In
particular, a joint model has been fitted successfully to the motivating dataset of the study, con-
sisting in 2415 monitoring subjects from the Spanish branch of ERSPC study. The main research
question was to explain the prostate cancer diagnosis risk on each of these subjects as a result of the
repeated measurements over time of the PSA biomarker, considering positive correlation between
the responses on the same subject.
The results showed that our fitted model is consistent with the literature and clinical knowledge.
On the one hand, the observed PSA is highly associated with the risk of being diagnosed of PCa.
On the other hand, there is a protective effect of the age and PSA interaction, consistent with
the age-varying effect of PSA on prostate cancer risk. Our study consisted of using joint modeling
techniques to 1) obtain an unbiased and efficient estimate of the the impact of PSA trajectories on
time to prostate cancer diagnosis, and 2) refine the prostate cancer free survival estimates by using
dynamic predictions based on the whole true history of PSA evolution for each subject.
The fitted joint model was validated by residuals tecniques, and predicted survival probabilities
were calculated. As longitudinal PSA information was collected for all subjects, the joint modeling
methodology has allowed to continuously update the predictions of their survival probabilities, and
therefore being able to discern between men with low and high risk for a disease diagnosis.
5.2 Future research
Our work can be considered a first step that should be followed by a more comprehensive modeling
process accounting for additional predictive factors measured over time like digital rectal exami-
nation, ultrasound biopsy test, prostate volume, family history and previous biopsy status among
others. In this respect, a very important aspect would be to have other baseline covariates in
further studies on this issue.
Another important aspect from our data is that the number of observations per subject was small, so
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that only 14% of them had three or more PSA measurements. More within subject measurements
would have prevented some potential bias in the random effect estimate and also would have
produced more precise estimates of the association parameter.
Even though we have focused on joint models with a relative risk submodel with a piecewise constant
baseline risk function for the event outcome, JM package form R software offers several other options
for the survival submodel as described in Section 3.4, such as Weibull or Gamma distributions.
Finally, it must be pointed out that extensions of the standard joint model approach can be con-
sidered. Thus, it is reasonably to consider not only the biomarker true value at specific time point
t to predict the subject-specific hazard, but also the particular slope (trend) of the longitudinal
trajectory up to this time.
Bibliography
Andersen, P. K. and Gill, R. D. (1982). Cox’s regression model for counting processes: a large
sample study. The Annals of Statistics, 10:1100–1120.
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N.,
Gelmann, E. P., Kvale, P. A., Reding, D. J., Weissfeld, J. L., Yokochi, L. A., O’Brien, B., Clapp,
J. D., Rathmell, J. M., Riley, T. L., Hayes, R. B., Kramer, B. S., Izmirlian, G., Miller, A. B.,
Pinsky, P. F., Prorok, P. C., Gohagan, J. K., Berg, C. D., and Team, P. P. (2009). Mortality
results from a randomized prostate-cancer screening trial. The New England Journal of Medicine,
360:1310–1319.
Berenguer, A., Luja´n, M., Pa´ez, A., Santonja, C., and Pascual, T. (2003). The Spanish contribution
to the European Randomized Study of Screening for Prostate Cancer. BJU international, 92:33–
38.
Brandt, L. J., Sheng, S. L., Morrell, C. H., Verbeke, G. N., Lesaffre, E., and Carter, H. B. (2003).
Screening for prostate cancer by using random-effects models. Journal of the Royal Statistical
Society: Series A, 166:51–62.
Breslow, N. (1974). Covariance analysis of censored survival data. Biometrics, 30:89–99.
Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg,
L., Kantoff, P., Konety, B. R., Murad, M. H., Penson, D. F., and Zietman, A. L. (2013). Early
detection of prostate cancer: AUA Guideline. American Urological Association, 190:419–426.
Chou, R., Croswell, J. M., Dana, T., Bougatsos, C., Blazina, I., Fu, R., Gleitsmann, K., Koenig,
H. C., Lam, C., Maltz, A., Rugge, J. B., and Lin, K. (2011). Screening for prostate cancer: a
review of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine,
155:762–771.
Cox, D. R. (1972). Regression models and life-tables. Journal of the Royal Statistical Society.
Series B (Methodological), 34:187–220.
Cox, D. R. (1975). Partial likelihood. Biometrika, 62:269–276.
Dempster, A. P., Laird, N. M., and Rubin, D. B. (1977). Maximum likelihood from incomplete
data via the EM algorithm. Journal of the Royal Statistical Society. Series B (Methodological),
39:1–38.
Efron, B. (1977). The efficiency of Cox’s likelihood function for censored data. Journal of the
American Statistical Association, 72:557–565.
Faucett, C. L. and Thomas, D. C. (1996). Simultaneously modelling censored survival data and
repeatedly measured covariates: A Gibbs sampling approach. Statistics in Medicine, 15:1663–
1685.
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., and Parkin, D. (2010). GLOBOCAN
2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon, France:
International Agency for Research on Cancer, 2010:29.
57
Bibliography 58
Garre, F. G., Zwinderman, A. H., Geskus, R. B., and Sijpkens, Y. W. (2008). A joint latent
class changepoint model to improve the prediction of time to graft failure. Journal of the Royal
Statistical Society: Series A (Statistics in Society), 171:299–308.
Harrell, F. E. (2001). Regression modeling strategies: with applications to linear models, logistic
regression, and survival analysis. Springer.
Harrington, D. P. and Fleming, T. R. (1982). A class of rank test procedures for censored survival
data. Biometrika, 69:553–566.
Harville, D. A. (1977). Maximum likelihood approaches to variance component estimation and to
related problems. Journal of the American Statistical Association, 72:320–338.
Heijmink, S. W., Fu¨tterer, J. J., Strum, S. S., Oyen, W. J., Frauscher, F., Witjes, J. A., and
Barentsz, J. O. (2011). State-of-the-art uroradiologic imaging in the diagnosis of prostate cancer.
Acta Onco´logica, 50:25–38.
Henderson, R., Diggle, P., and Dobson, A. (2000). Joint modelling of longitudinal measurements
and event time data. Biostatistics, 1:465–480.
Hsieh, F., Tseng, Y.-K., and Wang, J.-L. (2006). Joint modeling of survival and longitudinal data:
Likelihood approach revisited. Biometrics, 62:1037–1043.
Kalbfleisch, J. D. and Prentice, R. L. (2002). The statistical analysis of failure time data, 2nd
Edition, volume 360. John Wiley & Sons.
Kaplan, E. L. and Meier, P. (1958). Nonparametric estimation from incomplete observations.
Journal of the American Statistical Association, 53:457–481.
Laird, N. M. and Ware, J. H. (1982). Random-effects models for longitudinal data. Biometrics,
38:963–974.
Lindstrom, M. J. and Bates, D. M. (1988). Newton-Raphson and EM algorithms for linear mixed-
effects models for repeated-measures data. Journal of the American Statistical Association,
83:1014–1022.
Lipsitz, S. R., Fitzmaurice, G. M., Ibrahim, J. G., Gelber, R., and Lipshultz, S. (2002). Parameter
estimation in longitudinal studies with outcome-dependent follow-up. Biometrics, 58:621–630.
Little, R. J. and Rubin, D. B. (2002). Statistical analysis with missing data, 2nd edition. Wiley,
New York.
Luja´n, M., Pa´ez, A., Berenguer, A., and Rodriguez, J. A. (2012). Mortality due to prostate cancer in
the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Results after a 15-year follow-up. Actas Urolo´gicas Espan˜olas, 36:403–409.
Moyer, V. A. (2012). Screening for prostate cancer: US Preventive Services Task Force recommen-
dation statement. Annals of Internal Medicine, 157:120–134.
Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D., and Team, R. C. nlme: Linear and nonlinear mixed
effects models, 2012. R package version, pages 3–1.
Prentice, R. (1982). Covariate measurement errors and parameter estimation in a failure time
regression model. Biometrika, 69:331–342.
Proust-Lima, C. and Taylor, J. M. (2009). Development and validation of a dynamic prognostic tool
for prostate cancer recurrence using repeated measures of post-treatment PSA: A joint modeling
approach. Biostatistics, 10:535–549.
Bibliography 59
Rizopoulos, D. (2010). JM: An R package for the joint modelling of longitudinal and time-to-event
data. Journal of Statistical Software, 35:1–33.
Rizopoulos, D. (2011). Dynamic predictions and prospective accuracy in joint models for longitu-
dinal and time-to-event data. Biometrics, 67:819–829.
Rizopoulos, D. (2012a). JMbayes: Shared parameter models for the joint modeling of longitudinal
and time-to-event data using JAGS, WinBUGS, or OpenBUGS.
Rizopoulos, D. (2012b). Joint models for longitudinal and time-to-event data with applications in
R. CRC Press, Boca Rato´n, FL.
Rizopoulos, D., Verbeke, G., and Lesaffre, E. (2009). Fully exponential laplace approximations for
the joint modelling of survival and longitudinal data. Journal of the Royal Statistical Society:
Series B (Statistical Methodology), 71:637–654.
Rizopoulos, D., Verbeke, G., and Molenberghs, G. (2010). Multiple-imputation-based residuals and
diagnostic plots for joint models of longitudinal and survival outcomes. Biometrics, 66:20–29.
Roobol, M. J., van Vugt, H. A., Loeb, S., Zhu, X., Bul, M., Bangma, C. H., van Leenders, A. G.,
Steyerberg, E. W., and Schroder, F. H. (2012). Prediction of prostate cancer risk: the role of
prostate volume and digital rectal examination in the ERSPC risk calculators. European Urology,
61:577–583.
Santos Nobre, J. and da Motta Singer, J. (2007). Residual analysis for linear mixed models.
Biometrical Journal, 49:863–875.
Schabenberger, O. and Pierce, F. F. J. (2002). Contemporary statistical models for the plant and
soil sciences. CRC press.
Schro¨der, F. H., Hugosson, J., Carlsson, S., Tammela, T., Ma¨a¨tta¨nen, L., Auvinen, A.,
Kwiatkowski, M., Recker, F., and Roobol, M. J. (2012). Screening for prostate cancer de-
creases the risk of developing metastatic disease: findings from the European Randomized Study
of Screening for Prostate Cancer (ERSPC). European Urology, 62:745–752.
Schro¨der, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Ciatto, S., Nelen, V., Kwiatkowski,
M., Lujan, M., Lilja, H., Zappa, M., Denis, L. J., Recker, F., Paez, A., Maattanen, L., Bangma,
C. H., Aus, G., Carlsson, S., Villers, A., Rebillard, X., van der Kwast, T., Kujala, P. M.,
Blijenberg, B. G., Stenman, U. H., Huber, A., Taari, K., Hakama, M., Moss, S. M., de Koning,
H. J., and Auvinen, A. (2012). Prostate-cancer mortality at 11 years of follow-up. The New
England Journal of Medicine, 366:981–990.
Slate, E. H. and Turnbull, B. W. (2000). Statistical models for longitudinal biomarkers of disease
onset. Statistics in medicine, 19:617–637.
Swerdlow, S., Campo, E., Harris, N., et al. (2008). International Agency for Research on Cancer.
WHO classification of tumours of haematopoietic and lymphoid tissue, pages 1–439.
Therneau, T. (2012). Survival analysis, including penalised likelihood. R package.
Therneau, T. and Grambsch, P. (2000). Modeling survival data: extending the Cox model. Springer,
New York.
Tsiatis, A., Degruttola, V., and Wulfsohn, M. (1995). Modeling the relationship of survival to
longitudinal data measured with error. Applications to survival and CD4 counts in patients with
AIDS. Journal of the American Statistical Association, 90:27–37.
Bibliography 60
Tsiatis, A. A. and Davidian, M. (2004). Joint modeling of longitudinal and time-to-event data: An
overview. Statistica Sinica, 14:809–834.
Verbeke, G. and Molenberghs, G. (2000). Linear mixed models for longitudinal data. Springer.
Wulfsohn, M. S. and Tsiatis, A. A. (1997). A joint model for survival and longitudinal data
measured with error. Biometrics, 53:330–339.
Appendix A
DETAILS ON SOURCE DATASET CONFIGURATION
A.1 The two types of observations in PCa Dataset
In order to collect all the information provided by the ERSPC Spanish section, some artificial
observations (as additional rows) were introduced in our source data set. Thereby, there are two
types of observations:
1. Observations that correspond to visit dates
These correspond to observations that traditionally may occur in any database where there are
multiple records per person. Such observations correspond to regular monitoring visits, with
their corresponding PSA level and with known codes for the DRE and TRUS physical tests.
These rows are easily identifiable in our dataset because they are always associated with two
possible code pairs:
(RECTYP = 0 ; BIOPSY = 0): Visit in which a biopsy test was not recommended.
(RECTYP = 0 ; BIOPSY = 1): Visit in which biopsy test was recommended but not done.
The total number of such rows in PCa Dataset is 4673, unequally distributed among the 2415
subjects involved in the study. In practice, this is the information that, adapted in
the most convenient way for each analysis, has been used throughout this study in
order to describe correctly the survival and longitudinal approaches.
2. Artificial observations
These are dataset rows which were ”artificially” added to a given subject with the only purpose
of reporting the date of a specific event occurred in the historical profile of the subject. Possible
reasons that may lead to the addition of an artificial observation within specific subject were
the following:
• Observation that reports the date of a performed prostate biopsy:
– An observation which indicates the date that a subject underwent biopsy with negative
result is coded as (RECTYP = 0 ; BIOPSY = 2).
– An observation which indicates the diagnosis date of a screen-detected prostate cancer is
coded as (RECTYP = 0 ; BIOPSY = 3).
– An observation which indicates the diagnosis date of an interval prostate cancer is coded
as (RECTYP = 0 ; BIOPSY =NA).
• Observation that reports the date of the subject’s exclusion date from trial or his death date,
without having in both cases any relationship with prostate cancer event:
– An observation which indicates the exclusion date from trial is coded by RECTYP = 1.
– An observation which indicates the death date is coded by RECTYP = 2.
The total number of artificial rows in PCa Dataset is 1121, unequally distributed among the 2415
subjects involved in the study. This kind of rows were not finally included in the joint
modeling analysis carried out, although they are a very valuable data, both to better
understand the patterns of disease and for offering the basis for further work on this
issue.
61
Appendix A. Details on Source dataset configuration 62
A.2 Treatment of exclusions from the study
As already mentioned, the observations that only report exclusion dates are purely informative,
so the active active surveillance of prostate cancer incidence continued until 31/12/2007 (provided
that the exclusion had occurred before this study end).
Under the above assumption, there were recorded a total of 249 exclusions prior to study end on
31/12/2007, which were properly incorporated to the PCa Dataset as “artificial” rows using the
code RECTYP = 1.
On the other hand, during the data set debugging six individuals were found with an ordinary
visit recorded after his exclusion date. Since exclusion involves the ending of re-screening visits,
these observations were removed from our source data set alleging that that an exclusion is a
more rational criterion than a visit. In this respect, it must also be pointed out that three of the
removed visits were associated with not done biopsy recommendations, while the remaining three
visits resulted respectively in three negative biopsy tests.
Finally, the number of recommended but not done biopsies became 278 in our PCa Dataset versus
the 281 in the Spanish section from ERSPC trial, while negative biopsies were 584 versus the 587
listed in the mentioned trial.
A.3 Treatment of missing values
Some of the variables introduced in PCa Dataset contained missing values for certain observations,
both in visit rows and artificially added rows. Throughout the entire data set, these missing values
were coded using NA, but for the correct understanding of the PCa Dataset it is important to note
the row type within which the missing value appears:
1. Missing data that corresponds to an unknown value in a row of a specific subject:
These would be the missing values that traditionally may occur in any database. The reason
why in some records from our database there are unknown values for some variables, is only due
to available instruments or to protocol issues, so one can assume a pattern of the type Missing
Completely at Random (MCAR), without any relationship to development of prostate cancer.
2. Missing data from record dates (rows) that have been ”artificially” added to a given subject:
These rows had to be included in order to record the exact date of some specific events described
earlier. They are observations that do not represent an individual’s visit, and subsequently they
can not provide any information related to the covariates of interest. For this reason, it was
decided to codify with NA these above mentioned covariates.
A.4 Biopsies results’ distribution
The study involves active monitoring of the potential prostate cancer incidence in subjects through
sequential readings of their PSA level. Thereby, the subject was recommended a biopsy if his
PSA level was above the threshold established at the time of the visit. From the date of the first
study visits, on 19/02/1996, until the last visits day, on 21/10/2005, a total of 968 biopsies were
recommended over the course of 4673 occurred visits. Biopsies results’ distribution is shown in
Table A.1:
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Biopsies performed 684 (71.1%)
Biopsies with negative result 584 (85.4% / 60.7%)
Biopsies with positive result 100 (14.6% / 10.4%)
Biopsies recommended but not done 278 (28.9%)
Total 962 (100%)
Table A.1. Distribution of the biopsies’ results in the PCa Dataset.
The total number of biopsies performed in the study were 684: 584 (85.4%) from these had a
negative result and there were 100 (14.6%) which led to a prostate cancer diagnosis. Moreover,
there were 278 recommended but not done biopsies distributed among 242 different patients, so
10.0% of total 2415 subjects had at least one record with a recommended but not performed biopsy.
Finally, the distribution of 116 diagnosed prostate cancer cases was the following:
• Number of individuals with screen-detected prostate cancer: 100
• Number of patients with interval prostate cancer diagnosed: 16. From these group, there were
15 interval cancers diagnosed, whom joined one subject who did not present a positive biopsy
within the study but had prostate cancer as the cause of death in the death certificate.
A.5 Examples of profile description
Operating scheme of data set can be complex, specially if the reader is not familiar with it. Con-
sequently, this section proposes, by way of illustration, the description of the historical profile of
three subjects contained in the database. For this, their path were covered from first visit date
until its last record due to one of different possible ending scenarios.
The three subjects’ profiles chosen for illustration are 100, 138 and 275, so that their respective
associated records are shown in Table A.2:
ID RANDAT DATE RECTYP AGE PSA DRE TRUS BIOPSY FPSA PSARAT TIME CENS CANTYP GLE2
...
100 14/05/1996 24/05/1996 0 61.31 2.70 0 0 0 NA NA 72.92 0 0 0
100 14/05/1996 21/06/2001 0 66.39 5.10 0 0 1 NA NA 72.92 0 0 0
100 14/05/1996 20/11/2002 0 67.81 6.22 1 1 0 11.20 1.80 72.92 0 0 0
100 14/05/1996 19/12/2002 0 67.89 NA NA NA 2 NA NA 72.92 0 0 0
100 14/05/1996 25/02/2004 0 69.07 5.56 1 1 0 1.39 0.25 72.92 0 0 0
100 14/05/1996 09/03/2004 0 69.11 NA NA NA 2 NA NA 72.92 0 0 0
...
138 02/06/1996 12/06/1996 0 64.82 0.70 0 0 0 NA NA 69.54 0 0 0
138 02/06/1996 17/12/1999 1 68.34 NA NA NA NA NA NA 69.54 0 0 0
138 02/06/1996 02/03/2001 2 69.54 NA NA NA NA NA NA 69.54 0 0 0
...
275 30/10/1996 06/11/1996 0 58.62 2.10 0 0 0 NA NA 62.62 1 1 1
275 30/10/1996 04/10/2000 0 62.53 3.10 1 1 0 NA NA 62.62 1 1 1
275 30/10/1996 08/11/2000 0 62.62 NA 1 NA 3 NA NA 62.62 1 1 1
...
Table A.2. Records of individuals 100, 138 and 275 in the PCa Dataset.
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Personal history profile of subject 100:
The individual 100, assigned to the screening group on 14/05/1996, had his first visit on 24/05/1996
at the age of 61.31 years, with PSA = 2.70 ng/ml registered. According to the first protocol,
required neither biopsy (because his PSA ≤ 4 ng/ml) nor an early recall (PSA /∈ [3, 4] ng/ml).
He had a new visit on 21/06/2001 (later of theoretically four years between standard visits), and
recorded a total PSA level greater than the threshold under the second protocol: PSA = 5.10
ng/ml ≥ 3 ng/ml. He was then recommended a biopsy test but he rejected.
Due to the high serum level recorded in his second visit (and to the fact that he did not have
a biopsy), he was assigned to an early recall (within less than two years) which took place on
20/11/2002. He recorded then total PSA and PSARAT values above the thresholds established in
3rd protocol: PSA = 6.22 ng/ml ≥ 3 ng/ml and PSARAT = 1.80 ≥ 0.20. Thereby, he underwent
a biopsy on 19/12/2002, obtaining a negative prostate cancer diagnosis.
Since the high PSA value on his third visit and the subsequent negative biopsy result, he was send
to a new early visit on 25/02/2004, in which he was again recorded PSA and PSARAT values higher
than the maximum allowable thresholds: PSA = 5.56 ng/ml≥ 3 ng/ml and PSARAT = 0.25 ≥ 0.20.
Consequently, he was recommended a new biopsy test, which took place on 9/3/2004 and had a
negative result in relation to prostate cancer. Afterwards, the individual continued his stay in the
study until 31/12/2007, when he was 72.92.
After this history profile, it can be determined that the follow-up of the subject 100 extends from
the date of his first visit, at the age of 61.31 years, to the study end, aged 72.92 years, not having
been diagnosed with prostate cancer diagnosis during this period (this fact is represented with a
circle at next scheme).
1995 2000 2005 2010
End of study: 31/12/2007
24/05/1996
Ti = 61.31 Tf = 72.92
Follow-up of subject 100: 11.61 years
Time (years)
Figure A.1. Subject 100 folow-up within the observation window.
Personal history profile of subject 138:
The individual 138, assigned to the screening group on 02/06/1996, had his first and only visit
on 12/06/1996 at the age of 64.82, with PSA = 0.70 ng/ml. According to the first protocol, he
required neither biopsy (he had a PSA ≤ 4 ng/ml) nor an early recall (PSA /∈ [3, 4] ng/ml).
On 17/12/1999, this subject was excluded from further screening rounds due to unrelated causes
with prostate cancer, but continued under an active surveillance on the potential incidence of the
disease.
Finally, the subject died on 02/03/2001 at the age of 69.54 years without any prostate cancer
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symptoms.
After this information, it can be determined that the follow-up period of the subject 138 extends
from the date of his first visit until the date of his death (prior to the end of study), with no signs
of prostate cancer.
1995 2000 2005 2010
End of study: 31/12/2007
12/06/1996
Ti = 64.82
02/03/2001
Tf = 69.54
Follow-up of subject 138: 4.72 years
Time (years)
Figure A.2. Subject 138 folow-up within the observation window.
Personal history profile of subject 275:
The individual 275, assigned to the screening group on 30/10/1996, had a first visit on 06/11/1996
at the age of 58.62 years with PSA = 2.10 ng/ml. According to the first protocol required neither
biopsy (he had a PSA ≤ 4 ng/ml) or an early recall (PSA /∈ [3, 4] ng/ml).
He had a new visit on 04/10/2000 (four years later, as standard interval screenings indicates), and
recorded a total PSA level greater than the threshold under the second protocol: PSA = 3.10 ng/ml
≥ 3ng/ml. He was then recommended a biopsy test, performed on 08/11/2000 and with a positive
result: prostate cancer diagnosed when he was 62.62 years old. It is therefore a screen-detected
cancer type (CANTYP = 1), whose aggressiveness in this case is at a low level according to the
rescaled Gleason pattern (GLE2 = 1).
After this history profile, it can be determined that the follow-up period of the subject 275 extended
from his first visit date, at the age of 58.62 years, to date of his prostate cancer diagnosis when he
was 62.62 years old. Hence, this subject represented a complete data due that he experienced the
event of interest within the study.
1995 2000 2005 2010
End of study: 31/12/2007
06/11/1996
Ti = 58.62
08/11/2000
Tf = 62.62
Follow-up of subject 275: 4.01 years
Time (years)
Figure A.3. Subject 275 folow-up within the observation window.

Appendix B
R CODE FOR COMPUTATIONAL ANALYSES
B.1 Code for longitudinal analysis
# ============================================================= #
# ================ LONGITUDINAL DATA ANALYSIS =============== #
# ============================================================= #
# LOAD THE LIBRARIES
# ==================
library(nlme)
library(Hmisc)
# From the PCa Dataset information, the following variables are selected for each
# subject visits: OBS, ID, AGE0, LLPSA0, START, PSA, LLPSA, STOP, EVENT
# Read de subset of dimensions 4673x9 as a data frame:
lmm_data <- read.table(’cox_td_llpsa.txt’,header=T)
# Factorization of identifier code:
lmm_data$ID <- as.factor(lmm_data$ID)
# Translation:
lmm_data <- transform(lmm_data, AGE0=AGE0-45, START=START-45, STOP=STOP-45)
# Ghange the name for the further adaption to the JM package
colnames(lmm_data)[5] <- ’OBSTIME’
## MODEL WITH RANDOM INTERCEPT
## ===========================
lmm.1 <- lme(LLPSA~OBSTIME,random=~1|ID, data=lmm_data,
control=lmeControl(msMaxIter=5000, opt="nlminb",niterEM=5000))
summary(lmm.1)
summary(lmm.1)$tTable
lmm.1$logLik # 1160.039
# Fixed coefficients:
fixef(lmm.1)
# Random effects:
ranef(lmm.1)
# Global coefficients:
coef(lmm.1)
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## MODEL WITH RANDOM SLOPE
## =======================
lmm.2 <- lme(LLPSA~OBSTIME,random=~-1+OBSTIME|ID, data=lmm_data,
control=lmeControl(msMaxIter=5000, opt="nlminb",niterEM=5000))
summary(lmm.2)
summary(lmm.2)$tTable
lmm.2$logLik # 997.711
# Fixed coefficients:
fixef(lmm.2)
# Random effects:
ranef(lmm.2)
# Global coefficients:
coef(lmm.2)
# Comparison:
anova(lmm.1,lmm.2) # lmm.1
## MODEL WITH RANDOM INTERCEPT AND RANDOM SLOPE
## ============================================
lmm.3 <- lme(LLPSA~OBSTIME,random=~OBSTIME|ID, data=lmm_data,
control=lmeControl(msMaxIter=5000, opt="nlminb",niterEM=5000))
summary(lmm.3)
summary(lmm.3)$tTable
lmm.3$logLik # 1214.29
# Fixed coefficients:
fixef(lmm.3)
# Random effects:
ranef(lmm.3)
# Global coefficients:
coef(lmm.3) infividu:
# Comparison
anova(lmm.1,lmm.3) # lmm.3
anova(lmm.2,lmm.3) # lmm.3
B.2 Code for survival analysis
# ============================================================= #
# ================= SURVIVAL DATA ANALYSIS ================== #
# ============================================================= #
# LOAD THE LIBRARIES
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# ==================
library(survival)
library(Hmisc)
# From the PCa Dataset information, the following variables are selected
# at first visit of each subject: ID, AGE0, PSA0, LLPSA0, TIME, CENS
# Read de subset of dimensions 2415x6 as a data frame:
cox_llpsa0 <- read.table(’cox_llpsa0.txt’,header=T)
# Translations of time variables: AGE0 and TIME:
cox_llpsa0$AGE0 <- cox_llpsa0$AGE0-45
cox_llpsa0$TIME <- cox_llpsa0$TIME-45
# NON PARAMETRIC SURVIVAL ANALYSIS WITH ALL SUBJECTS
# ==================================================
# Data distribution
all <- survfit(Surv(TIME,CENS)~1,data=cox_llpsa0)
summary(all) # 116 diagnosed
# Kaplan-Meier Curve
par(oma=c(0.5,1,0,0),mar=c(4.5,4.5,3,2),las=1,
cex.main=0.9,cex.lab=0.9,cex.axis=0.9)
plot(all,xlim=c(0,40),conf.int=F,mark.time=T,
lty=1,col=1,lwd=2, lab=c(10,10,7), xaxt=’n’,
main=’Kaplan-Meier survival curve for the PCA Dataset’, xlab=’Age (years)’,
ylab=expression(paste(hat(S),"(t): Proportion without prostate cancer diagnosis")))
axis(1,at=c(0,5,10,15,20,25,30,35,40),labels=c(45,50,55,60,65,70,75,80,85))
segments(0,0.9137,29.8,0.9137, lwd=1, lty=2,col=1)
text(7,0.87,"0.914 (74.8 years)",col=1,cex=0.9)
legend("bottomright", y.intersp = 1.15,
title=expression(underline("Total number of subjects: 2415")),
c("Prostate cancer diagnosis: 116 (4.8%)", "Right-censored data: 2299 (95.2%)"),
inset=0.025, bg=’gray95’,cex=0.9, bty=’white’ )
# NON PARAMETRIC SURVIVAL ANALYSIS STRATIFYNG BY PSA0 CUT-OFF
# ===========================================================
# New dichotomous variable, named GROUP:
cox_llpsa0$GROUP=ifelse(cox_llpsa0$PSA0>=3,1,0)
sum(cox_llpsa0$PSA0<3) # 2151 (89.07%)
sum(cox_llpsa0$PSA0>=3) # 264 (10.93%)
# Kaplan Meier curves by GROUP
pdf(’tercils_AGE0.pdf’,width=7,height=5)
par(oma=c(0.5,1,0,0), mar=c(4.5,4.5,3,2), las=1,
cex.main=0.9, cex.lab=0.9, cex.axis=0.9)
plot(survfit(Surv(TIME,CENS)~GROUP,cox_llpsa0),xlim=c(0,40),
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col=1:2,conf.int=F,mark.time=F, lwd=1.5, xaxt=’n’,
main=bquote(bold(paste("Kaplan-Meier survival curves by ",
bolditalic(PSA),"0 cut-off"))), xlab=’Age (years) at first visit’,
ylab=expression(paste(hat(S),"(t): Proportion without prostate cancer diagnosis")))
summary.G0 <- summary(survfit(Surv(TIME,CENS)~GROUP,subset(cox_llpsa0,GROUP==0)))
summary.G1 <- summary(survfit(Surv(TIME,CENS)~GROUP,subset(cox_llpsa0,GROUP==1)))
lines(c(summary.G0$time,36.7),c(summary.G0$lower,0.927),col=1,lty=2)
lines(c(summary.G0$time,36.7),c(summary.G0$upper,0.965),col=1,lty=2)
lines(c(summary.G1$time,36.24),c(summary.G1$lower,0.643),col=2,lty=2)
lines(c(summary.G1$time,36.24),c(summary.G1$upper,0.770),col=2,lty=2)
axis(1,at=c(0,5,10,15,20,25,30,35,40),labels=c(45,50,55,60,65,70,75,80,85))
text(5,0.90,"0.946 (74.80 years)",col=1,cex=0.8)
text(5,0.66,"0.704 (71.18 years)",col=2,cex=0.8)
segments(0,0.9459,36.7,0.9459,lty=3,lwd=1,col=1)
segments(0,0.7039,26.2,0.7039,lty=3,lwd=1,col=2)
rug(0.9459, ticksize = -0.02, side = 2,col=1)
rug(0.7039, ticksize = -0.02, side = 2,col=2)
dev.off()
# Log-rank test by PSA0 cur-off:
sf <- survdiff(Surv(TIME,CENS)~GROUP,cox_llpsa0,rho=0)
print(sf)
# NON PARAMETRIC SURVIVAL ANALYSIS STRATIFYNG BY AGE0 TERTILES
# ============================================================
# Kaplan Meaier curves by AGE0 tertile
cox_llpsa0$AGE0t <- with(cox_llpsa0,cut2(cox_llpsa0$AGE0,c(10,15)))
levels(cox_llpsa0$AGE0t)[c(1:3)]<-c(’Low AGE0’,’Medium AGE0’,’High AGE0’)
# Kaplan-Meier curves by AGE0 tertile:
pdf(’tercils_AGE0.pdf’,width=6,height=5)
par(oma=c(0.5,1,0,0), mar=c(4.5,4.5,3,2), las=1,
cex.main=0.9, cex.lab=0.9, cex.axis=0.9)
plot(survfit(Surv(TIME,EVENT)~AGE0t,cox_llpsa0), xlim=c(0,40),
conf.int=F, mark.time=F, xaxt=’n’,
col=1:4,lwd=c(2,2,2),lab=c(10,10,7),
main=bquote(bold(paste("Kaplan-Meier survival curves by ",
bolditalic(AGE), "0 tertiles"))), xlab=’Age (years)’,
ylab=expression(paste(hat(S),"(t): Proportion without prostate cancer diagnosis")))
axis(1,at=c(0,5,10,15,20,25,30,35,40),labels=c(45,50,55,60,65,70,75,80,85))
legend("bottomright",y.intersp = 1.2,levels(cox_llpsa0$AGE0t),col=1:3,lty=1,lwd=2,
inset = 0.01, bg=’gray95’,cex=0.9)
dev.off()
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# SEMI-PARAMETRIC SURVIVAL ANALYSIS WITH ALL SUBJECTS
# ===================================================
# PH Cox model with the baseline covariate LLPSA0
cox1.llpsa0 <- coxph(Surv(TIME,CENS)~LLPSA0,cox_llpsa0)
summary(cox1.llpsa0) # p-value < 0.0001
cox1.llpsa0$loglik # -758.3271
# PH Cox model with the baseline covariate AGE0xLLPSA0
cox2.llpsa0 <- coxph(Surv(TIME,CENS)~AGE0*LLPSA0,cox_llpsa0)
summary(cox2.llpsa0) # p-value < 0.0001
cox2.llpsa0$loglik # -774.429
B.3 Code for joint model analysis
# ============================================================ #
# ================ JOINT MODEL ANALYSIS ==================== #
# ============================================================ #
# LOAD THE LIBRARIES
# ==================
library(nlme)
library(survival)
library(JM)
library(plotrix)
# From the PCa Dataset information, the following variables are selected at first
# visit of each subject:
# OBS, ID, AGE0, LLPSA0, OBSTIME, LLPSA, STOP, TIME, EVENT, CENS
# Read de subset of dimensions 4673x10 as a data frame:
jm_llpsa <- read.table(’jm_llpsa.txt’,header=T)
# Change name of START avriable to OBSTIME variable:
colnames(jm_llpsa)[5]<-’OBSTIME’
# Translations:
jm_llpsa <- transform(jm_llpsa, AGE0=AGE0-45,
OBSTIME=OBSTIME-45, STOP=STOP-45, TIME=TIME-45)
# First observations from each subject:
jm_llpsa.id <- jm_llpsa[!duplicated(jm_llpsa$ID),]
# SURVIVAL MODEL WITH AGE0xLLPSA0
coxfit.id <- coxph(Surv(TIME,CENS)~AGE0:LLPSA0,data=jm_llpsa.id,x=TRUE)
# LONGITUDINAL MODEL WITH RANDOM INTERCEPT
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# ========================================
lmm.1 <- lme(LLPSA~OBSTIME,random=~1|ID, data=jm_llpsa,
control=lmeControl(msMaxIter=5000, opt="nlminb",niterEM=5000))
# LONGITUDINAL MODEL WITH RANDOM SLOPE
# ====================================
lmm.2 <- lme(LLPSA~OBSTIME,random=~-1+OBSTIME|ID, data=jm_llpsa,
control=lmeControl(msMaxIter=5000, opt="nlminb",niterEM=5000))
# LONGITUDINAL MODEL WITH RANDOM INTERCEPT AND SLOPE, UNSTRUCTURED D MATRIX
# =========================================================================
lmm.3 <- lme(LLPSA~OBSTIME,random=~OBSTIME|ID, data=jm_llpsa,
control=lmeControl(msMaxIter=5000, opt="nlminb",niterEM=5000))
# JOINT MODELS WITH LLPSA0xAGE0 SURVIVAL BASELINE COVARIATE
# ==========================================================
jm.int.intercept <- jointModel(lmm.1 ,coxfit.id, timeVar="OBSTIME",
method="piecewise-PH-aGH",control = list(iter.EM=5000,optimizer=’nlminb’))
summary(jm.int.intercept)
confint(jm.int.intercept)
jm.int.slope <- jointModel(lmm.2, coxfit.id, timeVar="OBSTIME",
method="piecewise-PH-aGH",control = list(iter.EM=5000,optimizer=’nlminb’))
summary(jm.int.slope)
confint(jm.int.slope)
jm.int.int_slo <- jointModel(lmm.3, coxfit.id, timeVar="OBSTIME",
method="piecewise-PH-aGH",control = list(iter.EM=5000, optimizer=’nlminb’))
summary(jm.int.int_slo)
confint(jm.int.int_slo)
# VALIDATION OF THE FITTED JOINT MODEL: RESIDUAL PLOTS
# ====================================================
pdf(’residuals_TFM.pdf’,width=7,height=5)
plotResid <- function(x,y,col.loess=1,...){
plot(x,y,pch=19,col=’gray55’,cex=0.5,...)
lines(lowess(x,y), col=col.loess,lwd=3)
abline(h=0, lty=3, col=1, lwd=1)
}
par(mfrow = c(2,2), oma=c(0,1,0,0), mar=c(4.5,3.75,3,3.25), las=1,
cex.main=0.85, cex.axis=0.85, cex.lab=0.85)
resSubY <- residuals(jm.int.intercept,
process = "Longitudinal",type = "stand-Subject")
fitSubY <- fitted(jm.int.intercept, process = "Longitudinal",
type = "Subject")
plotResid(fitSubY, resSubY, xlab = "Fitted values", ylab ="Residuals",
xlim=c(0,1.5),xaxt=’n’,ylim=c(-4,4),
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main = "Standardized subject-specific residuals vs fitted values")
axis(1,at=c(0,0.3,0.6,0.9,1.2,1.5),label=c(’0.0’,0.3,0.6,0.9,1.2,1.5))
resMargY <- residuals(jm.int.intercept,
process = "Longitudinal",type = "stand-Marginal")
fitMargY <- fitted(jm.int.intercept, process = "Longitudinal",
type = "Marginal")
plotResid(fitMargY, resMargY, xlab = "Fitted values", ylab =
"Residuals",xlim=c(0.3,0.8),xaxt=’n’,ylim=c(-6,6),yaxt=’n’,
main = "Standardized marginal residuals vs fitted values")
axis(1,at=c(0.3,0.4,0.5,0.6,0.7,0.8),label=c(0.3,0.4,0.5,0.6,0.7,0.8))
axis(2,at=c(-6,-3,0,3,6),label=c(’-6.0’,’-3.0’,’0.0’,’3.0’,’6.0’))
resMartT <- residuals(jm.int.intercept,
process = "Event", type = "Martingale")
fitSubY <- fitted(jm.int.intercept, process = "Longitudinal",
type = "EventTime")
plotResid(fitSubY, resMartT, xlab = "Fitted values", ylab = "Residuals",
xlim=c(0,1.5),xaxt=’n’,ylim=c(-1.5,1.5),yaxt=’n’,
main = "Martingale residuals vs fitted values")
axis(1,at=c(0,0.3,0.6,0.9,1.2,1.5),label=c(’0.0’,0.3,0.6,0.9,1.2,1.5))
axis(2,at=c(-1.5,0,1.5),label=c(’-1.5’,’0.0’,’1.5’))
resCST <- residuals(jm.int.intercept,
process = "Event", type = "CoxSnell")
sfit <- survfit(Surv(resCST, CENS) ~ 1, data = jm_llpsa.id)
plot(sfit, mark.time = FALSE, conf.int = TRUE, lty = 1:2,
xlab = "Cox-Snell Residuals", ylab = "Survival probability",
xlim=c(0,1.4),xaxt=’n’, main = "Survival function of Cox-Snell Residuals")
curve(exp(-x), from=0, to=max(jm_llpsa.id$TIME), add=TRUE, col=1, lwd=2)
axis(1,at=c(0,0.2,0.4,0.6,0.8,1,1.2,1.4),label=c(’0.0’,0.2,0.4,0.6,0.8,1.0,1.2,1.4))
dev.off()
# SURVIVAL DYNAMICAL PREDICTIONS
# ==============================
# Change the name of variable ID by id:
colnames(jm_llpsa)[2]<-’id’
# The four registres for subject ID=id=845:
jm_llpsa[jm_llpsa$id==845,c(2,4:9)]
set.seed(123) # We set the seed for reproducibility
survPrbs <- survfitJM(jm.int.intercept,
newdata=jm_llpsa[jm_llpsa$id==845, ], M=200)
# The plot method depicts the estimates of the conditional survival probabilities.
pdf(’survival_556.pdf’,width=7,height=5)
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par(oma = c(0, 1, 0, 1),cex.main=1, cex.lab=1, cex.axis=1)
inicio <- 15
plot.survfitJM(survPrbs,lty = c(1:2,3,3),
main=expression(paste(’Conditional survival probabilities for subject ’,
italic(i),’=556’)), xlim=c(inicio,40), col=rep(’gray55’,4), lwd=c(2,2,2,2),
conf.int = TRUE, xaxt=’n’,yaxt=’n’)
axis(1, at=c(inicio,25,30,35,40), label=c(’0’,’70’,’75’,’80’,’85’))
axis.break(1, 19.5, style="zigzag", brw=0.05)
axis(1, at=c(27.5,32.5,37.5), label=c(’’,’’,’’),tck=-0.015)
axis(2, at=c(0,0.2,0.4,0.6,0.8,1), label=c(’0.0’,0.2,’0.4’,’0.6’,’0.8’,’1.0’),las=1)
segments(24.58, 0, x1 = 24.58, y1 = 1, col=1, lty=3, lwd=1)
mtext(’Age (years)’,las=0,side=1,line = 2.75, cex=0.9)
text(21.6,0.5,’t = 69.58 years’,cex=1)
dev.off()
